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ABSTRACT
Encapsulation of antimicrobial agents (simple antiseptics and more specific
antibiotics) within micro-scale and nano-scale containers may provide prolonged and
more evenly distributed drug release. One of such containers proposed at Louisiana Tech
is natural halloysite clay nanotubes. Halloysite is an aluminosilicate tube with a length of
approximately 1 pm, outer diameter o f approximately 50 nm, and internal lumen of
15 nm. The chemical composition o f halloysite is similar to more common claykaolinite, and it can be described as rolled sheets o f kaolinite. Halloysite, loaded with
drugs inside its lumen, has shown aqueous release o f the loaded chemicals over 10-20
hours and, with formation o f the tube-end stoppers, for days. Typical loading efficiency
for drugs is 5-10 wt%. An attractive aspect of halloysite nanotubes is an economically
viable, green and biocompatible material. However, the size o f halloysite clay tube is not
in the safe size range(less than 1 pm) for injection.
In this study, halloysite tubes were used as nanocontainers loaded with antiseptics
and antibiotics, and the controlled release of these drugs was monitored. The popular
antiseptic brilliant green was loaded into halloysite at 5 wt% and provided sustained
release over 24 hours. The release profile was fitted with an exponential first-order curve
time rate o f approximately 3.5 hours. Measurement o f antibacterial efficiency o f the
brilliant green tubule nano-formulation on S. aureus bacterial culture demonstrated that

the antibacterial action was extended up to 72 hours (as compared with 4-5 hours activity
for non-encapsulated brilliant green). In order to further decrease the release rate, tubeending stoppers were developed. The formation o f benzotriazole-copper coating on
halloysite nanotubes provided additional encapsulation and slowed release o f the loaded
substances to 100-200 hours.
Silver ions have strong antimicrobial efficiency, and we used halloysite as a silver
carrier. First, we developed template synthesis of 15 nm diameter silver nanorods inside
the tube lumen and, second, spherical 5-10 nm diameter silver nanoparticles on the
nanotube external surface. The composites o f silver nanorods encased in halloysite tubes
with the polymer paint were prepared, and the composite coating enhanced antimicrobial
activity and increased the tensile strength. An additional advantage was that the coating
containing 5 wt% silver-loaded halloysite did not change color after light exposure,
contrary to the sample prepared with unshelled silver nanoparticles (so, we described
protective core-shell effect). Halloysite nanotube templates have an additional potential
for scalable manufacturing of ceramic encapsulated metal nanorods for composite
materials.
In the next stage of this research project, we studied loading and slow release o f
two antibiotics (ciprofloxacin and gentamicin) from halloysite nanotubes. First, we
demonstrated enhanced efficiency o f antibiotics loaded in these clay nanotubes for
multidrug-resistant gangrene bacteria (longer time action). Afterwards, we developed
doping o f bone cements (polymethylmethacrylate and tricalcium phosphates) with
5-8 wt% o f antibiotics loaded halloysite. This approach allowed us synergetic
improvement o f adhesivity and strength o f the bone composites in combination with

longer time (200 hours) antibiotics release. This is the time typically needed for after
surgery treatment of implant-bone conjunctions (bone glue).
Orthopedic grade polymethylmethacrylate (PMMA) bone cement, admixed with
prophylactic antibiotics (e.g. gentamicin), is widely used in hip and knee replacement
surgery. For cement loaded with antibiotics, there is a critical need to improve its
structural integrity and to control antibiotic release. In particular, preventing reaction of
the drug with the cement during its polymerization is important. The resulting composite
material has a significantly larger material strength and adhesion on cow bone surface
and provides sustained release of antibiotics loaded within the halloysite lumen. Besides,
the addition o f halloysite significantly (ca. 20 0 C) reduces the PMMA polymerization
temperature. When added directly, many common antibiotics have carbonyl groups that
react with monomers or decompose during free radical polymerization. This construct
allows separation o f antibiotics from other components o f the cement and hence provides
a larger choice o f antibiotics. In future work, antibiotics combinations in the nanotubes
could be mixed in the cement with enhanced antibacterial action for a customized,
sustained, “a la carte” multiple drug delivery. Halloysite nanotubes have no cytotoxic
effects placing halloysite on par with other well-known materials, such as bioactive glass,
silica and hydroxyapatite.
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CHAPTER 1

INTRODUCTION

1.1

Motivation and Background

Advancing medical technology is improving longevity and quality o f life, making
people feel happier. However, much o f the tissue in our bodies, such as heart, liver, lung
and bones, has only limited ability to reproduce when damaged. To repair these tissues,
tissue engineering becomes more and more important. Among other tissues, bones can be
replaced with inorganic materials (implants). Ceramics, metals and plastics have been
used as bone implants, but neither compares with the original bone. Therefore, bone
cement, a new material, will be examined for minor bone repair and connection o f
implants to bones.
Advances in surgical techniques and population longevity have both increased the
need for and the number o f orthopedic and dental procedures worldwide [1-3]. The
greater number o f high risk individuals in the patient population has also led to an
increase in the need for additional operations due to device/implant failure or infection.
Revision procedures are also needed in the case o f complicating conditions, such as bone
infection and re-sorption, loss o f bone mass, bone cancer reoccurrence or failure o f new
bone tissue to grow.
Antibiotics mixed in bone cement are widely used in hip and knee surgery to treat
or prevent infection. However, there is a restricted choice o f antibiotics to be mixed with
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polymethylmethacrylate (PMMA) and calcium phosphate (CP) cements because they are
often inactivated during composite formulation (e.g., MMA polymerization), and are
released over a short time period. In addition, adding antibiotics will decrease the
strength o f PMMA and CP cements. Thus, there is a critical need to improve antibiotic
activity and release time from the bone cements without losing its strength.

1.2

Objectives

First, we are introducing the concept o f natural halloysite clay tubule
nanocontainers that will be loaded with different antiseptics and antibiotics for longer
active release times. Second, we doped antibiotic loaded halloysite into bone cements
(polymethylmethacrylate-PMMA or calcium phosphate-CP) for their antimicrobial
protection during the most dangerous first two-week period (standard time) after implant
surgery. This construct allows the antibiotics to be separated from the polymerization
step allows a broader range of antibiotics that would otherwise be incompatible with the
polymerization step. Many common antibiotics have carbonyl groups that react with
MMA or decompose during free radical polymerization. Polyelectrolyte tube
encapsulation and stopper formation at the tube ends will optimize the release rate within
a few days to ten days. Antibiotic combinations could be mixed in the cement with
enhanced antibacterial action for a customized, “a la carte” multiple drug delivery over a
sustained period. Halloysite doping will preserve cement strength and increase bone and
implant adhesiveness. The tensile strength o f halloysite-antibiotic composites does not
deteriorate, as compared with pure cement. Clay nanotubes have shown no cytotoxic
effects (up to a very high concentration o f 0.8 mg/ml) placing halloysite on par with other
well-known materials, such as bioactive glass and hydroxyapatite.

We loaded halloysite tubes with different antibiotics and dope them into PMMA
or CP cement powder at a 5-8 wt% ratio (0.6-1 wt% antibiotic content in the composite).
Halloysite loaded with antibiotics provides a simple method for their combinations in
base cements. The clay tubes isolate the drugs and serve as containers for sustained
release which is controlled by the tube openings. To extend drug release, the tube will be
encapsulated with polyelectrolytes, urea-formaldehyde or benzotriazole cross-linking.
Antibiotics-loaded halloysite admixed in PMMA or CP will provide sustained release up
to 100-250 hours, and with enhanced release at crack locations in the cement. The new
nanocomposite bone cement may incorporate any number o f desired medical factors
(singly or in combination) including antibiotics, anti-inflammatories, and imaging agents.

1.3

Outline of Dissertation

Chapter 1 introduces the motivation and some background information about this
research work. The research goal and the organization o f this dissertation are shown.
Chapter 2 gives a brief literature review covering the knowledge needed for this
dissertation: halloysite clay nanotube description, loading and release o f bioactive
chemicals from halloysite, antiseptics and antibiotics loading into clay nanotubes and
their additional encapsulation to extend drug release from tens to hundreds of hours,
halloysite-polymer mixtures and bone cement composites: PMMA and CP bone cement.
Chapter 3 gives research methods and instrumentations for experimentation and
analysis.
Chapter 4 describes using simple drug-antiseptics loading into halloysite tubes
and slow release. Additional tube-end stopper formation increases the release time and
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improves drug loading efficiency. The comparison o f the enhanced antibacterial
efficiency of drug loaded halloysite and free drugs are presented.
Chapter 5 describes the method of using halloysite nanotubes as a template to
synthesize alternative antimicrobial-silver nanorods inside the halloysite lumen. The paint
composite, doped with core-shell silver nanorods, presents extended antibacterial
properties and protection from light exposure.
Chapter 6 demonstrates the advantages o f making PMMA and CP bone cement
composites with antibiotics loaded halloysite. The composites show a slow release of
loaded gentamicin o f hundreds of hours, and enhance the mechanical properties o f the
cement, such as tensile strength, adhesive strength to bone and titanium nail, and
lowering the polymerization temperature. For tricalcium phosphate-CP bone cement,
anoutstanding8 times tensile strength increase was demonstrated, which is especially
important for this relatively mechanically weak bone implant.
Chapter 7 concludes the results of the dissertation, and recommends some future
works.

CHAPTER 2

LITERATURE REVIEW

2.1

Bone Cement

Bone cement has been used very successfully to anchor artificial joints (hip joints,
knee joints, shoulder and elbow joints) for more than 50 years. The bone cement fills the
free space between the prosthesis and the bone and plays the important role o f an elastic
zone, such that the mechanical properties become very important to ensure that the
artificial implant remains in place over the long term.
2.1.1

Polymethylmethacrylate (PMMA) Bone Cement
Polymethylmethacrylate (PMMA) bone cement has been used in orthopedic

surgery since 1958 [l-3].Its biocompatibility and mechanical properties have made it a
remarkable and indispensable tool in orthopedic repair, specifically in joint replacement
arthroplasty. During surgery, PMMA is added to fill the void between the implant and the
bone providing a stable construct. PMMA is commonly used for fixation in hip and knee
replacement surgery.
The two-stage knee arthroplasty revision for infection, with implant removal and
an interval o f antibiotic therapy before implant replacement, was invented later and is a
standard clinical procedure [4]. Antibiotics were added to cement to provide local
antibiotic delivery in addition to intravenous doses [2-5]. This practice has improved
implant survival and reduced reinfection rates. The non-porous PMMA bone cement
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allows for release o f only a portion of the antibiotics which are evenly distributed
throughout the cement [6]. For example, current cement formulations release 75% of that
released within the first 24 hours [7-9].
2.1.2

Calcium phosphate (CP) Bone Cement
Calcium phosphate (CP) bone cements and bone graft substitutes have become

materials o f choice for bone repair, because of their biocompatibility and
osteoconductivity. Generally, a CP formulation contains calcium and phosphorous
based ingredients in powder form, which on mixing with an aqueous medium,
forms a workable, self-setting putty. The ingredients dissolve in the medium, making it
supersaturated with the desired calcium phosphate which is re-precipitated inside the
mass. The growth of the calcium phosphate phase as entangled crystallites helps the
putty to retain its strength and shape. The design o f a calcium phosphate cement is done
on the basis o f the calcium-phosphorous ratio o f the final precipitate and the
physicochemical characteristics of precipitation. We have chosen a and /?-tricalcium
phosphate as the bone cement material, which shows a desired setting time, hardness,
chemical stability and biofunctionality [10].
2.1.3

Limitations of Antibiotics Mixed into Bone Cement
Prophylactic antibiotics are added while mixing the PMMA bone cement

together. Gentamicin, ciprofloxacin and colistimethate are used to treat various types o f
bacterial infections, particularly gram-negative infections. All of these antibiotics are
available in a powdered form that can be mixed into the cement base. Once pure PMMA
is mixed with 0.5-1 wt% o f antibiotics and used in a procedure, the antibiotics will leak
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from the bone cement into surrounding areas [4,5], The local concentration o f antibiotics
is usually sufficient to initially kill the bacteria left in the operative wound.
The surgical bone cement formulations face major challenges in meeting demands
for more functional, bio-instructional and longer-lasting products. Current treatment
modalities of mixing antibiotics in commercial bone cement have three significant
limitations. First, the addition o f antibiotics to bone cement leads to a weakening of
PMMA and calcium phosphate bone cement, in particular, to a loss of mechanical
strength. In addition, sustained releases o f the antibiotics from the current bone cements
are available for only a short time period, providing no long-term protection against
infection [4,5]. Second, mixing-in the antibiotics uniformly is difficult, even with a
sonicator. The non-porous nature of PMMA and other bone cements not only contributes
to the limited release of the antibiotics, but also causes the antibiotics to be unevenly
distributed throughout the cement. Mixing antibiotics intra-operatively into bone cement
presents a certain risk o f allergic reactions, cement mechanical failures, toxicity, and
development o f bacterial resistance. Third, many common antibiotics have carbonyl
groups that react with PMMA monomers or decompose during free radical
polymerization when added directly. This construct will allow separation of antibiotics
from other components o f the implants and hence provide a larger choice o f antibiotics.
During polymerization, the composite temperature could increase up to 80 °C, which is
harmful to the adjacent tissues.
PMMA and CP material strength is also compromised by cement additives [11].
There is an essential drawback in direct loading of many antibiotics to pre-cement MMA
mixtures because o f the reaction with these monomers during free radical polymerization
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(all antibiotics containing carboxyl groups are decomposed). The goal for bone cement
halloysite composites is to achieve a more controlled, sustained release o f antibiotics
without compromising implant strength. Therefore, the composite will enable the use of a
wider variety o f antibiotics without their decomposition.

2.2

Microcapsules for Loading of Healing Agents into Polymeric Matrix

Microencapsulation of healing agents was under intensive development for
polymer composites. The first example o f capsule-based feedback bulk material was
developed with the dicyclopentadiene (DCPD)-Grubbs’ first-generation catalyst system
by White, et al. [12]. In a series of papers describing autonomic feedback o f DCPD
healing agent and Grubbs’ catalyst, Brown, et al. [13] reported high healing efficiencies
for bulk polymers. Moll, et al. [14] developed a self-sealing composite by incorporating
DCPD-filled capsules into epoxy. Rong, et al. [15] incorporated epoxy resin-filled
capsules in an epoxy matrix containing a thermally-activated imidazole catalyst.
Beiermann, et al. [16] extended the multicapsule PDMS system to a self-sealing
laminated composite by dispersing encapsulated tin catalyst di-n-butyltindilaurate. A
separate system with latent functionality was developed by incorporating thermallypolymerizable epoxy spheres into epoxy materials; these oxidize upon release, yielding a
corrosion-preventing film [17]. Mesoporus Si 0 2 nanoparticles were also used for
encapsulated benzotriazole and other drugs, and incorporated them into a protective solgel matrix [18]. However, polymer microcapsules are soft and often ruptured by shear
forces upon mixing with the polymers, causing premature release o f their content. The
state-of-the-art represents the application of large

( > 2 0

pm) capsules and requires

mechanical opening which is not convenient for medical applications. We will use
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smaller ( < 1 pm) tubule containers, endowed to provide effective long lasting drug
release.

2.3

Halloysite Nanotubes

Halloysite occurs naturally as a hydrated mineral with the idealised chemical
formula of Al2 Si2 0 5 (0 H)4 ' 2 H2 0 . It is similar to kaolinite except for the presence o f an
additional water monolayer between adjacent layers. Morphologically, halloysite tubes
are rolled aluminosilicate sheets with 15-20 adjacent layers in their walls. Heating
halloysite to 120 °C results in evaporation o f the interlayer water and in a smaller
(0.7 nm) spacing in the multilayer tube walls of the dehydrated halloysite [11, 19-39].
The tubular structure with external diameters of 50-100 nm is clearly evident
(Figure 2-1 a, b). The length o f tubes ranges from 0.5 to 1.5 pm. Lumen diameter is 15 to
25 nm and its volume consists 15-30% o f the tube volume (it may be adjusted with
selective lumen etching) [37, 38]. In Figure 2 -lb one can see the periodic multilayer
nature o f the halloysite wall as well as views of the internal aluminol (Al-OH) and
external siloxane (Si-O-Si) surfaces. The periodicity in the individual layer packing,
determined with X-ray analysis, was found to be 0.70±0.02 nm, which corresponds to
dehydrated halloysite. Elemental composition (atomic %) of the halloysite is: Al, 18.5;
Si, 19.1; O, 62.2. Brunauer-Emmett-Teller (BET) surface area of the halloysite sample
was 65±10 m2/g [23,24],
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Figure 2-1: a-b TEM and SEM images of halloysite tubes with detailization (c) halloysite
tube lumen (scale bar is 25 nm) (d) chemical structure of halloysite.
Figure 2-2 shows the zeta-potential for halloysite nanotubes, silica and alumina
nanoparticles [34] at different pH. The zeta-potential of halloysite acts just like silica
nanoparticles because the chemical on the external surface of halloysite is silica based.
Halloysite has a negative charge at pH 7.
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Figure 2-2: Zeta-potential for halloysite nanotubes, silica and alumina nanoparticles [34].
2.4

Halloysite Biocompatibility

Halloysite is a natural material and it does not add contamination risk to the
environment. Kommireddy, et al., used halloysite as a substrate for cell attachment and
proliferation to test its biocompatibility [39]. In vitro cytotoxicity testing is one o f the
important biological test methods for checking the biocompatibility o f a material, as per
International Standard Organization (ISO) standards. The outside surface o f halloysite
nanotubes contains silica, which makes it negatively charged. However, for the
cytotoxicity study, both negatively charged halloysite (raw halloysite) and positively
charged halloysite (through coating with polycations like poly-L-lysine and protamine
sulphate) were used to examine the surface interaction o f the halloysite with the
cells [40]. These tests were conducted on MCF-7 cells [34], and the results are shown in
Figure 2-3. The percentage o f live cells, as determined by Celltiter-96 reagent, was
measured for various concentration o f testing agents; raw halloysite, poly-L-lysine coated
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halloysite, protamine sulphate coated halloysite and NaCl as a negative control. NaCl was
not a good negative control because it is water soluble; however, halloysite is insoluble in
water. In all cases, the halloysite was non-toxic to the cells, even with concentrations as
high as 100 pg/ml. In addition, a more comprehensive study on halloysite toxicity
showed that even after cells ingest halloysite into the cells cytoplasm, the cells remain
alive [34],
120-1
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Figure 2-3: Viability assay o f MCF-7 cells on halloysite nanotubes and halloysite coated
with cationic polylysine (PLL) and protamine sulfate (PSO4) (after 24 hrs) [34].
2.5

Halloysite Encapsulate and Sustain Release of Antibiotics

Based on the hollow structure o f halloysite, halloysite nanotubes can be used as
nanocontainers to load with a broad variety of substances for sustained and slow release.
The substances can range from simple organic and inorganic molecules, to high
molecular weight polymers, and biologically active substances including drugs, enzymes
and DNA [19]. A typical method to load chemicals in halloysite is the vacuum method.
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In the vacuum method, the first step is to add dry halloysite into a saturated solution o f
the chemical, and mix the suspension thoroughly by stirring or sonication. Second, place
the suspension in a vacuum chamber for 10-30 minutes, which allows small air bubbles
to be removed from the halloysite nanotubes. Third, vent the vacuum chamber to
atmospheric pressure, during this process the chemical solution will enter into the lumen
and load the chemical within the tube. Finally, repeat these steps 3-4 times to increase the
loading efficiency. After loading, the halloysite is washed to remove the chemical
remaining attached to the external wall. After drying, the chemical loaded into the
halloysite will be remaining. Loaded halloysite will release under aqueous environment,
with the release lasting approximately 10-50 hours [40-46], The release kinetics o f the
chemical from the loaded halloysite follows first order kinetics with exponential function:
R — Moo(l — e~kt), where Moois the amount of active agent released at infinite time (i.e.
amount loaded within lumen) and k is the release rate constant.

2.6

Formation of Tube Ending Stopper

Previous research has shown that halloysite nanotubes have a good ability to
encapsulate chemicals and allow the slow release of these chemicals over long period
time. The addition o f stoppers on the end o f the halloysite tubes can significantly extend
the release time. Figure 2-4 shows halloysite tube endings coated with glucose complex,
which is an ideal stopper for covering only the ends of the tubes. Stoppers can also be
formed on loaded halloysite by coating the whole tube with nanoflims or nanoshells.
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Figure 2-4: SEM and TEM of halloysite nanotubes ending with a glucose complex.
2.6.1

Use o f the Laver-by-Laver Technique to Form a Stopper
The external surface of halloysite is silica based, so halloysite has a negative

charge. Using the Layer-by-Layer (LbL) technique (Figure 2-5), halloysite can be
effectively coated by sequential adsorption o f positively and negatively charged
polyelectrolytes. The multilayers of polyelectrolytes will form a shell encapsulated,
loaded halloysite, working as a stopper to decrease the release of loaded substance [47].

Figure 2-5: Scheme o f halloysite LbL-modification with polycation and polyanion, (e.g.,
red PEI/ blue PSS).
2.6.2

Metal-imidazole and Metal-triazole Form Stopper
Metal ions can interact with imidazoles and triazoles to form a thin film complex

(Figure 2-6). This film complex can be coated on the external halloysite surface by
rinsing the halloysite with both compound solutions [23, 24, 26, 31]. The complex of
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BTA-Cu is very strong and stable. Ammonia solution can be used to dissolve this
complex.

Figure 2-6: Chemical structure benzotriazole-copper complex.
2.7

Altering the Halloysite Lumen Property

To improve the loading efficiency o f halloysite, we need to improve the lumen
properties, such as lumen size, internal charge, hydrophobicity.
2.7.1

Increasing Lumen Size by Selective Etching
A disadvantage o f halloysite is that the lumen volume is only 10-15% o f the total

volume, so the loading efficiency is limited by the lumen volume. To improve the loading
efficiency of halloysite, the lumen volume can be increased. Because the external and
interior chemistry of halloysite differ (inner: alumina; outer silicon oxide), we can
selectively etch the inner alumina to enlarge the lumen size [37, 48-52]. Figure 2-7 a, b
show the TEM images of sulfite acid etched halloysite, Figure 2-7 c shows the lumen
diameter distribution o f sulfite acid etched halloysite. At the same time, the loss o f
alumina leads to a larger negative charge, which can increase the inner loading efficiency
o f positively charged chemicals.
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Figure 2-7: Sulfate acid etching increases the lumen diameter(a) before etching ,(b) after
etching), (c) Lumen diameter distribution shows the average lumen diameter of halloysite
is increased from 7-15 nm to 15-25 nm [37].
2.7.2

Modifying the Hydrophobicity of Halloysite
Natural halloysite is hydrophilic; therefore to load a hydrophobic substance inside

o f the halloysite lumen is very difficult, resulting a low loading efficiency. Selective
modification o f the halloysite inner lumen with octadecyl phosphonic acid (Figure 2-8),
dopamine, or ionic surfactants will cause the inner lumen to become hydrophobic
[34, 38, 53-63], Figure 2-9 shows the release profile o f ferrocene from halloysite and
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halloysite-ODP over 48 hours [38]. The ODP-modified halloysite can absorb about twice
as much hydrophobic ferrocene than unmodified halloysite. This result suggests that the
ODP can successfully change the inner lumen to a hydrophobic state and, in turn,
increase the loading efficiency for hydrophobic chemicals.
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Figure 2-8: Schematic of modified halloysite inner lumen with octadecyl phosphonic acid
[38],
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Figure 2-9: Release profile o f the ferrocene from halloysite and halloysite-ODP over 48
hr [38],
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2.8

Biopolymer Halloysite Nanocomposite

Halloysite nanotubes already have been proven to be biocompatible, dope loaded
bioactive substances halloysite into biopolymers (amylose, DNA, pectin) can make
biocomposites with functional release o f loaded substances from the halloysite [64-71].
The additional halloysite added can improve mechanical strength and also provide
functional properties by release o f bioactive substances from halloysite. These “green”
nanocomposites with sustained release o f bioactive agents may find applications in
cosmetics, bone implants, dentistry, for animal medicine formulation, plant nutrition,
marine antifouling and other antimicrobial coatings.
2.8.1

Layer-bv-Laver of Halloysite-Polycation Multilayers
The halloysite external shell has high negative charge. Thus, halloysite particles

can be used as ions for thin film synthesis using the LbL-technique combined with
positive charged biocompatible polycation or proteins (similar to Figure 2-5) [72,73],
2.8.2

Cast Halloysite-Biopolymer Composite from Solution
Most o f the natural polymers decompose at high temperature without melting,

thus, cast halloysite-biopolymer composite from polymer solution become the most
common preparation method [74, 75], Many researchers have already demonstrated that
adding 10-50 wt% halloysite into biopolymers, such as starch, chitosan, gelatin, pectin,
cellulose, and humic acid [71, 76-81], the mechanical and thermal properties o f the
composite significantly improved. For example, 4-5 wt% halloysite added in halloysitegelatin composite, the tensile strength and elastic modulus increased to 13 and 300 MPa,
respectively, compared with gelatin at 9 and 130 MPa, respectively. Figures 2-10 and
Figure 2-11 show SEM images o f Low-density polyethylene (LDPE) halloysite
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composites and Ethylene vinyl acetate (EVA) halloysite composites. Halloysite has very
good dispersion in the polymer matrix at 5-10 wt%. However, if the ratio o f halloysite is
up to 50 wt%, some halloysite aggregation will appear which will cause weak points and
the composite will become easy to break at these points.
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Figure 2-10: SEM image o f Low-density polyethylene (LDPE) with 5 wt% (left) and
1 0 wt% (right) halloysite.
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Figure 2-11: SEM image o f Ethylene vinyl acetate (EVA) with 5 wt% (left) and 10 wt%
(right) halloysite.
2.9

Halloysite-biopolymer composite for drug delivery

A typical loading efficiency o f drug in halloysite nanotubes is 5-15 wt%, and
release is within 10-50 hours. After adding loaded halloysite into biopolymer to form the
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composite, the release rate will decrease and last for months, or even years. First, the
loaded halloysite tubes need an aqueous environment to start the release process. In the
well dispersed polymer/halloysite composite, most of halloysite tubes are located in the
matrix, which makes them delay to start the release. Only the halloysite tubes near the
outside surface of the composite can start the release process fast. Second, after the inside
halloysite tubes release the drugs, these drugs have to go through the matrix in order to
release from the composite. For example, a tetracycline loaded halloysite chitosan
poloxamer composite drug delivery system was studied. This composite was capable o f
delivering antibiotic for up to 2.5 months and retained its sterilants over 9 months [82].

2.10

Halloysite Bone Cement Composite

What is desired is bone cement that has been augmented with material that can
add strength to prevent mechanical failure, significantly increase adhesion, decrease heat
effects, and provide a sustained release o f loaded drugs. The material used to augment the
bone cement must be biocompatible, without causing deleterious tissue changes or having
toxic or injurious effects. In this study, halloysite nanotubes are used as an additional
additive mix with polymethylmethacrylate (PMMA) and tricalcium phosphate (CP) bone
cement to make a composite to solve the problems above.

CHAPTER 3

M ETHODS AND INSTRUM ENTATION FOR EXPERIM ENTATION
AND ANALYSIS
This chapter describes the instruments and methods used in these projects.

3.1

Benchtop Vacuum Station

The method used to load a substance into halloysite nanotube in this dissertation
is a vacuum method. Add powdered halloysite into a concentrated drug solution, mixed
well by using stirring or sonication, then apply vacuum using a benchtop vacuum pump
(Figure 3-1). Keep vacuum for 15-30 minutes, allowing air bubbles to be removed from
the halloysite lumen. During the breaking of the vacuum, the drug solution will replace
into the halloysite lumen and be sustained. Repeat these steps three times, followed by
twice rinsing with DI water to remove the drugs adsorbed on the external surface of the
halloysite. Finally, dry the samples. The dry samples will sustain the loaded substance.
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Figure 3-1: Benchtop Vacuum Station

3.2

Ultraviolet Visible Spectroscopy

In order to study the release kinetics of the substance from the halloysite, an
ultraviolet visible spectrophotometer (Figure 3-2) is used to determine the amount of
drugs released from the halloysite and halloysite/polymer composites. The ultravioletvisible spectrophotometer is used for examine samples in the visible and ultraviolet
regions o f the electromagnetic spectrum. In UV-Vis spectroscopy, the wavelength and
maximum absorbance of compounds are determined by examining electronic transitions.
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Figure 3-2: UV-vis Spectrophotometer (Agilent Technology, 2012).
3.3

Tensile Strength Meter

Figure 3-3 shows the tensile strength meter (ADMIT Corp, 2008) used in this
study. The tensile strength meter is used to examine the mechanical properties o f the
halloysite/bone cement composites. The maximum loaded force of this machine is
2000 lb. The basic function of the tensile strength meter is to apply tension and
compression to a material. There are also attachments to allow measurement of adhesive
strength.
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Figure 3-3: Tensile Strength Meter (ADMIT Corp, 2008).
3.4

Contact-Angle Measurement System

Figure 3-4 shows the contact-angle measurement system used in this study. This
instrument is used to measure the water contact angle of the halloysite/bone cement
composite surface to determine hydrophobicity. The water drop size is controlled by the
system and the water drop size range is 0.5-5 pi.
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Figure 3-4: Contact-Angle Measurement System (Data Physics, Future Digital Scientific
Corp, 2005).
3.5

Nitrogen & Helium Porosity Meter

Figure 3-5 shows the nitrogen & helium porosimeter used in this study. The
nitrogen & helium porosimeter is used to measure the surface area and pore size. In this
study, a Nova 2012, Quatachrome Instrument is used to measure the halloysite nanotube's
surface area and average pore size.
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Figure 3-5: Nitrogen & Helium Porosimeter (Nova 2012, Quatachrome Instrument)
3.6

Scanning Electron Microscope Hitachi S-4800

Figure 3-6 shows the scanning electron microscope (SEM) Hitachi S-4800 used in
this project. The SEM uses an electron beam as an alternative to light to form images.
The electron beam, which is produced by an electron gun at the top o f the microscope,
passes through electromagnetic fields and lenses to focus on the sample. When the
sample is scanned by the electron beam it will emit X-rays and electrons, and the X-rays
and electrons are collected by suitable detectors as signals. These signals are used to form
images on a monitor screen. In this study, the SEM is used to examine morphology o f
halloysite nanotubes and halloysite/bone cement composites.

Figure 3-6: Scanning Electron M icroscope (Hitachi S-4800).

3.7

Transmission Electron Microscopy Libra-120

Figure 3-7 shows the transmission electron microscopy (TEM) Libra-120 used
this project. The TEM is another electron microscope, in which the electron beam is
transmitted through the sample, interacting with the sample as it passes through. The
interaction o f the electrons transmitted through the sample forms an image. In this
project, the TEM is used to examine the morphology of halloysite nanotubes.

Figure 3-7: Transmission electron m icroscopy (L ibra-120).

3.8

X-ray Diffraction XRD (Bruker-D8)

Figure 3-8 shows the X-ray diffraction system (Bruker-D 8 ) used in this research.
X-ray diffraction uses x-ray scattering techniques for materials characterization and
quality control o f crystalline or non-crystalline material. In this study, we used XRD to
characterize halloysite nanotubes, and modified halloysite nanotubes.

Figure 3-8: X-ray diffraction instrument (Bruker-D 8 ).

CHAPTER 4
SUSTAINED RELEASE OF ANTISEPTICS FROM
HALLOYSITE NANOTUBES
4.1

Introduction

Halloysite nanotubes are naturally occurring clay nanotubes found in several
deposits worldwide [19, 34,43]. The Dragon mine in Utah, alone, has over 2 billion tons
o f halloysite deposits making it economically viable for large scale production. Among
other templates studied for biomineralization, drug release, and tissue engineering,
halloysite has been undeservedly forgotten. Halloysite is a two-layered aluminosilicate,
chemically similar to kaolin, and has a predominantly hollow tubular structure in the
submicron range [11,34]. Halloysite nanotubes typically display an inner diameter
ranging from 15-50 nm, an outer diameter from 10-30 nm and a length between 500—
2000 nm [11,19-36],
Halloysite lumen provides a large capillary force for polar liquids (e.g. for water,
capillary pressure is in the range o f 100 - 500 atm) to aid in loading aqueous chemicals
inside the tubes. At pH above 2.0, it has a negative surface charge characterized by
electrical zeta-potential o f ca.—40 mV, which allows good dispersibility in water, polar
polymers and other media. Halloysite nanotubes have a large surface area of 60-70 m 2 /g.
These clay nanotubes can be loaded with different chemicals at 10-30 wt% and can be
used for sustained and release [19,34,47,83,84]. Tube loading efficiency can further be
increased with lumen enlargement using acid etching o f alumina layers [37]. Halloysite
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tubes are biocompatible as was checked on different cell cultures [39] and worms [34],
Surface chemistry, morphology and biocompatibility makes this nanomaterial an
excellent candidate for nanopore controlled release o f drugs, proteins and DNA with
release time exceeding 50 hours [47,83,84], Controlled release has been achieved using
several methods such as, silanization o f lumen to alter inner wall hydrophobicity or
synthesis o f artificial caps at tube ends [38,54],
In this study, we investigated halloysite as potential nanocontainers for loading
with brilliant green to provide slow release for extended antimicrobial activity. Metalbenzotriazole nanofilms have been studied as tube end stoppers to provide controlled
release reaching 200 - 300 hours. Such extended release allowed drastically increased
antimicrobial efficiency o f antiseptics.

4.2
4.2.1

Materials and Methods

Materials:
Halloysite has been obtained from Applied Minerals. Brilliant green, aspirin,

amoxicillin, ciprofloxacin, gentamicin, Iodine, benzotriazole, copper sulfate, tryptic soy
broth (TSB), and fluoresceine diacetate (FDA) were obtained from Sigma Aldrich.
Propidium iodide (PI) was obtained from Fluka. NaCl (SmartSpec™ 3000) was obtained
from BioRad. Plate reader: FluostarOptima (BMG Latch), and FLx800 was used for
checking bacterial cell viability. Cells were imaged with Nikon Eclipse TE 2000-U
inverted fluorescent microscope (Japan) equipped with CCD OI-17-EM monochrome
digital camera. Halloysite has been characterized with SEM (Hitachi 4800 FESEM) at
5 kV acceleration voltage.
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4.2.2

Loading Procedures
Brilliant green (200 mg) was dissolved in 10 ml acetone. 500 mg o f halloysite

was then added to the solution and thoroughly mixed followed by sonication for
30 minutes. The solution was placed in a vacuum chamber at 100 torr for 30 minutes. Air
bubbles were removed from the halloysite pores causing the drug solution to enter within
the lumen. After 30 minutes the vacuum was released and the suspension was taken out
from the vacuum chamber to be kept at standard atmosphere for 15 minutes. This vacuum
cycle was repeated three times followed by washing with DI water to remove any
unloaded antibiotic. Samples were placed in an oven at 50 °C for drying. The dried
sample was milled to a fine powder. Figure 4-1 shows a typical procedure o f load active
agents into halloysite nanotube.

\o ;Ooooooohi

HaSoysite in concentrate
drag solution

Vacuum to toad drag
solution m halloysite hsnen

Washing to remove
the drug on the suface

Drying loaded hafloysite

Figure 4-1: Loading procedure of active agents into halloysite nanotube.
4.2.3

Tube Encapsulation Benzotriazole-Copper Complexation
Halloysite was additionally encapsulated with benzotriazole-copper film to

provide controlled release (Figure 4-2). Nanotubes loaded with antiseptics were washed
with benzotriazole solution in acetone and followed by aqueous CUSO4 . Nanoporous film
•y,

has been formed by the interaction of adsorbed benzotriazole with copper ions (Cu ).
Antibiotic release is achieved through the pores existing in the film. The structure o f this
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film has been described in [26], Pore size (i.e. release rate) has been controlled by
varying the concentrations o f the benzotriazole and Cu (II).
Cu*2 Cu' 1

BTA BTA RTA

Cu*2 c u '2
Cu(BTA film)

BTA V

BTABTABTABTA

'

Cu'

BTA
p o res o n film
BTA
BTA
Halloysite loaded
w ith antibiotics

A dsorption o f benzotriazole (B IA )

A dsorption of co p p er ions

BTA reacts w ith Cu(ll) to form nanofilim
base o n BTA(Cu) complex

Figure 4-2: Formation of caps on antibiotic loaded halloysite tubes.
4.2.4

Drug Release from Flalloysite
Drug release experiments were conducted by stirring 50 mg o f antibiotic loaded

halloysite ini ml of deionized water (DI). At each reading, the supernatant was removed
by centrifugation at 7000 rpm and fresh DI water added. The collected supernatant was
analyzed by UV-Vis spectroscopy (Agilent 8453) at 625 nm wavelength for the amount
o f brilliant green released.
After 72 hours o f release, nanotubes were dispersed in 50 ml o f DI water and
sonicated in ultrasonic bath for 30 minutes. Then the supernatant was collected by
centrifugation at 5000 rpm. This process was repeated one more time to normalized
1 0 0

% release.

4.2.5

Cultivation o f Staphylococcusaureus
Bacteria were cultivated in tryptic soy broth (TSB, Sigma) at 37 ° C according to

manufacturer protocol. 30 g of rehydrated media was dissolved in 1L o f DI water and
sterilized at 121 ° C for lh. A day before the experiment, bacteria was inoculated into
fresh broth and grown overnight. Concentration o f cells was determined by UV
spectrophotometric measurement at 600 nm (SmartSpec™ 3000, BioRad) with
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conventional coefficient o f 1 o.u. being equal to 108 CFU/ml. Purity o f culture was
checked by standard Gram-staining technique.
4.2.6

Kinetic Viability Assay
A 5 ml aliquot of cells at a concentration o f 104 CFU/ml was used for each

experiment. Dried loaded tubes were placed into tubes containing 104 CFU/ml and
cultivated at 37° C in shaker-incubator during 24-72 h. After every 24 hours 1 ml aliquots
were collected and the replacement of the old media aseptically by fresh nutrient media
followed. The remaining 4 ml of sample was centrifuged for 5 min at 8000 rpm. The
supernatant was removed and aseptically replaced by 5 ml fresh TSB, vortexed, and
incubated.
4.2.7

Live/Dead Assay
Live/dead cell ratio was monitored by fluoresceine diacetate/propidium iodide

(FDA/PI) double staining. FDA is a non-fluorescent ester which is able to pass through
cell membranes and become fluorescent after intracellular esterase cleavage. PI stains
only membrane compromised cells. First, 0.5 ml o f each sample was washed by 0.85%
NaCl twice followed by centrifugation at 7000 rpm. Then, 2.5 pi of FDA was added to
each sample from a stock-solution of 10 mg/ml in acetone (final amount o f FDA 50 pg)
and incubated for 20 min at room temperature. After that, 2.5 pi of PI stock-solution
(1 mg/ml in water) was added to each tube and incubated for 10 min. Finally, 100 pi of
each sample were dispensed in 96-well black plate in three replicates and fluorescence
intensity was measured at 540 nm for FDA (excited at 485 nm) and at 600 nm for PI
(excited at 548 nm). Live/dead cell ratio was represented as the relative ratio o f green/red
fluorescence units.
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4.2.8

Fluorescent Microscopy
Nikon Eclipse TE 2000-U (Japan) inverted fluorescent microscope equipped with

Cool Snap ES Photometric monochrome digital camera was used to visualize treated cells
using FDA/PI double staining of S. aureus cells. Before microscopic observation, cells of
108 CFU/ml concentration were incubated in TSB nutrient media supplemented with free
brilliant green (BG), BG loaded halloysite, and BG loaded halloysite capped with
benzotriazole-copper stoppers for 3 hours. Weights o f these additives were adjusted so
that each sample contain663 pM o f BG, assuming that loading efficiency o f sample
without stopper is 5% while loading efficiency of sample with stopper is 15% (values for
loading efficiencies were obtained from BG release studies). Following this, cells were
washed twice with sterile 0.85% NaCl and centrifuged at 7000 rpm for 2 min. Then
precipitated cells were resuspended in 0.5 ml 0.85% NaCl sterile solution. To this
solution 0.75 pi o f PI (stock solution in DMSO 20 mM) and 0.5 pi of FDA (stock
solution in acetone

10

mg/ml) were added, vortexed and incubated for 2 0 min at room

temperature. Samples were analyzed using fluoresce microscopy using broadband blue
filter (Xex = 480 nm, Xem = 535 nm) for viable cells and green filter (Xex = 540 nm,
Xem = 620 nm) for dead cells. Pictures were colored using MetaMorph software. As a
o

control sample, we used S. aureus cells at a concentration of 10 CFU/ml incubated at
room temperature for 3 hrs without the addition of halloysite and BG.

4.3

Results and Discussion

Preliminary results on brilliant green were obtained by Shraddha Parshottambhai
Patel in our IfM nanoassembly lab-L7, co-advised by Dr. Mills and Dr. Lvov. According
to Patel's dissertation tilted "Nanotechnology In Regenerative Medicine," it was shown
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the release profiles of pristine halloysite loaded with brilliant green, chlorhexidine, iodine
curcuma longa, povidone iodine, amoxycillin and doxycyclin. In my dissertation work,
we extended and improved this technique with encapsulating loaded halloysite nanotubes
with additional end-stoppers to slow-down antiseptics release time and to increase
loading efficiency by selective lumen etching. All drugs release results presented in this
Chapter are obtained by myself.
4.3.1

Release o f Active Agents
In this study, several drugs were used to load in the halloysite. The release results

show loaded halloysite can slow the release o f the loaded substance for 5-48 hours, as
compared to free drugs release in water within only 15 minutes. Figure 4-3 shows all the
drug formulas used in this study.
♦

H jC ^N

CH3

B rillian t green

A sp irin

C ip r o flo x a c in

AcOH

AcOH

C h lo r h e x id in e d ia c e ta te salt h y d ra te

CH3
A m o x ic illin

G en tam icin

Figure 4-3: Molecular structures of the drugs used in this study.
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4.3.2

Brilliant Green Release from Halloysite with BTA-Cu Stopper
A commonly used antiseptic agent - brilliant green (BG) was studied in three

different forms; free microcrystals, loaded within halloysite lumen, and loaded within
halloysite followed by sealing with BTA-Cu nanofilms as nanotube end caps. As one can
imagine, the level o f encapsulation increases in the above mentioned order. Free
microcrystals have no shells for sustained release, while halloysite and BTA-Cu films
provide tight control over the brilliant green release rate (Figure 4-4). Crystals o f brilliant
green reached

1 0 0

% release within 15 minutes; however, release from halloysite lumen

was about 70% in 3 hours. BTA-Cu stoppers allowed only 4% of brilliant green release
within 3 hours.
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Figure 4-4: Brilliant green releases in water, from loaded halloysite, from loaded
halloysite with BTA-Cu stopper.
Factors affecting BTA-Cu film formation, i.e. the concentrations o f the BTA and
Cu (II), were studied in detail. Concentrations o f BTA and CuSCT* were varied from
40-170 mM and 4-80 mM ranges, respectively. Figure 4-5 a, b present BG release
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curves from halloysite treated with these films. The release rate gradually decreases at a
fixed Cu (II) concentration o f 4 mM upon increasing the BTA concentration
(Figure 4-5 a), as expected. A tighter film forms at higher BTA concentrations leading to
smaller pores, retarding the release rates. Surprisingly, an opposite phenomenon was
observed at high Cu (II) concentration of 80 mM. In this case BG release rate is slowest
at 41 mM BTA concentration and gradually increases with the increasing o f its
concentration. This might be explained by the variation o f BG loading efficiency upon
formation o f the caps. As one would expect, faster film formation occurs upon using
higher concentrations of BTA, which results in lesser amounts of leaked BG during film
formation. Fligher loading efficiency causes a higher concentration gradient between the
inner pores and the external solution, which is the major driving force for drug release.
Indeed, loading efficiencies o f the samples capped with 41mM, 82 mM and 165 mM
BTA and 80 mM CUSO4 solutions increase from 6.5 wt% to 15.8 wt%. Compared with
loaded halloysite without stopper, the loading efficiency was only 3wt%. From here we
conclude that two main factors affect the BG release rate; loading efficiency and BTA-Cu
film porosity. Loading efficiency dominates at higher Cu (II) concentrations, while film
porosity dominates at lower concentrations. These effects allow for long lasting release of
active agents loaded within the halloysite lumen, and they can be generalized to all the
bioactive agents.
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Figure 4-5: (a) BTA-Cu stopper which has various concentrations o f BTA and 80 mM
CUSO4 . (b) halloysite with BTA-Cu stoppers which have various concentrations o f BTA
and 4 mM CuS 0 4 .(c) Brilliant green release from microcrystals BTA-Cu encapsulated
without halloysite tubes.
Release curves in Figure 4-4 and Figure 4-5 can be described by using first order
kinetics: R = Moo(l —e~kt), where Mm is the amount o f active agent released at infinite
time (i.e. amount loaded within the lumen) and k is the release rate constant. Release
profiles are composed of two parts: Rapid release in the initial

6

hours and slow release in

the remaining time. Different constants o f the reaction rate were used to describe these
two parts o f the release profiles. They are presented in Table 4-1. Initial release is
associated with brilliant green that is deposited close to tube endings or external pockets
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o f the tubes. These molecules are loosely attached to the halloysite surface and release
quickly in water.

Table 4-1: First order release parameters M„-k of different brilliant green release
samples.

S a m p le

K

M ^ ( r e m a in )

k 2 (r e m a in )

L E (w t% )

(6hours)

(6hours)

B G r e le a se in w ater

122

10.4

-

-

-

B G r e le a se fro m h a llo y site

83

0 .8 4

93

0.37

2.8%

165 m M B T A + 8 0 raM Cu

3.5

0 .6 5

3 .8

0 .4 0

1 5 .8 %

82 m M B T A + 8 0 m M Cu

7 .0

0 .5 9

7 .7 5

0 .3 9

11.5%

41 m M B T A + 8 0 m M Cu

17

0 .5 3

2 0 .2

0.27

6 .5 %

165 m M B T A + 4 m M Cu

18

0 .5 5

24

0.21

10.8%

8 2 m M B T A + 4 m M Cu

12.5

0 .5 5

15.5

0.2 7

8 .6 %

41 m M B T A + 4 m M Cu

11

0 .6 5

12 .7

0 .3 3

7 .8 %

4.3.3

Antibacterial Effect o f Brilliant Green Loaded Halloysite
Figure 4-6 shows live/dead ratio o f Staphylococcusaureus cells with different BG

loaded halloysite samples with and without stopper and free brilliant green. We used
fluoresceine diacetate and propidium iodide double staining to assess the value o f the
live/dead cell ratio using plate reader assay. Kinetic experiments include centrifugation
and discarding o f old media steps, which leads to an unavoidable loss o f cells causing by
turn change in relative fluorescence intensity of the living cells. According to the results
of the fluorescent plate reader assay, both brilliant green loaded halloysite with and
without stopper suppress the growth o f S. aureus, as compared with untreated cells. In
addition, free brilliant green only suppress the growth o f S. aureus within approximately

5 to 10 hours; after that, S. aureus cells grow similar to the untreated sample. Kinetic
viability test data has shown that capped BG-loaded tubes significantly inhibit bacteria
growth, as compared to both untreated control (165 mM BTA 80 mM Cu) and uncapped
sample (BG HNTs). Bacteria growing in nutrient media supplemented by equal amount
o f free BG continue growing after 1st media replacement. Moreover, it has been observed
that S. aureus decolorize free brilliant green for 5 hours, whereas media containing
loaded halloysite tubes remains green within 72 hrs. Previous studies have shown that the
inhibitory effect o f brilliant green is connected with the colored form of the dye [85].

MM 2 4

h o u rs
48 h o u rs
■ ■ 72 h o u rs

Untreated 165mM BTA 165mM BTA BG HNTs
cells
+80mM Cu +4mM Cu

Free BG

Figure 4-6: Kinetic o f live/dead S. aureus cells ratio treated with brilliant green loaded
halloysite with and without stopper and free brilliant green. Data are represented as
Average±2SE. Control - untreated cells.
Samples were visualized using Fluorescence microscopy with broadband blue
filter ((Xex~ 480 nm, Xem = 535 nm) for live cells and green filter (Xex = 540 nm,
Xem = 620 nm) for dead cells. In the images presented in Figure 4-7, green dots represent
live cells while red dots indicate dead ones.
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( .

Figure 4-7: Fluorescent micrographs o f samples untreated (A, B) and treated S. aureus
cells with 663 pM o f free brilliant green (C, D), loaded halloysite nanotubes without
stopper (E, F) and loaded halloysite nanotubes with stoppers (G, H). Scale bar - 10 pm.
Pseudo-colors.
According to fluorescence microscopy data, one can clearly see that the samples
treated with loaded halloysite (capped and uncapped) and free brilliant green contain
dead membrane compromised cells as compared with the control sample. The control
contained 3±1% dead cells whereas the free BG treated sample, BG-HNTs treated and
165 mM BTA 80 mM Cu loaded capped HNTs treated cells, contained 80±5%, 65±3%
and 68±4% dead cells, respectively. The significantly large amount o f dead cells in the
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sample treated free BG can be explained by immediate action of BG, but, according to
the kinetic viability assay, bactericide action o f BG lasts less than 24 h and is eliminated
after the 1st media replacement (Figure 4-6). It was also noticed that some cells have
double green/red emission. This phenomenon can be explained in that brilliant green
partially damages the cell membrane and enables propidium iodide to penetrate through
the formed gaps and stain the nucleic acids inside the cells.
Other commonly used antiseptics, such as tetracycline and benzotriazole, were
also loaded into halloysite nanotubes at 5-6 wt% and have shown 6-10 hours release time
even without additional encapsulation. This proves that, for a number o f simple
antiseptics, we may drastically increase their antibacterial activity over many tens to and
hundreds o f hours. This is especially important for hospital-acquired infections (with the
well-known nosocomial infections) which drives even further the use o f antimicrobials in
medical applications.
4.3.4

Other Loaded Drugs into Halloysite
In this study, some other drugs (aspirin, amoxicillin, ciprofloxacin, gentamicin,

Iodine) also were used. All drugs used the vacuum method (section 2.5) in order to be
loaded into halloysite.
Figure 4-8 shows the release of aspirin from loaded halloysite. About 90% of
aspirin released within the first hour.
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Figure 4-8: Release of aspirin from halloysite.
Figure 4-9 shows the release o f amoxicillin from halloysite. Compared with free
amoxicillin release in water in only 15 minutes, the loaded amoxicillin releases 90% in
three hours.
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Figure 4-9: Release o f amoxicillin from halloysite and in water (W. Wenbo results
extending Dr. Patel's approach).

45

Figure 4-10 shows the release of iodine. Free iodine is released in water within
about 5 minutes, whereas iodine loaded halloysite release 90% in 1 hour. However,
loaded iodine with an additional stopper significantly reduced the release to 30% in
1

hour.
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Figure 4 -10: Release of iodine from water, halloysite, and halloysite with BTA-Cu
stopper (W. Wenbo results extending Dr. Patel’s approach with new formulation).
Two dyes, bromocresol purple, and bromothymol blue (Figure 4-11) were also
used to study stoppers. Figure 4-12 shows that the BTA-Cu stopper significantly reduced
the release o f both dyes.
OH

HO

Br

OH
CH 3

Bromocresol purple

Bromothymol blue

Figure 4-11: Formula of bromocresol purple, and bromothymol blue.
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Figure 4-12: Release o f bromocresol purple, and bromothymol blue from halloysite with
BTA-Cu stopper.
Next, sulfate acid was used to etch the halloysite and determine the impact on
loading and release [37]. Based on how much aluminum oxide has been etched, the
processed samples were grouped as 10, 35, 45, and 60% etching. These modified
nanotubes were tested for drug loading and compared the release and loading efficiency
with untreated halloysite. Figure 4-13 shows chlorhexidinediacetate salt hydrate release
from halloysite, with 10% etching, 35% etching, and 45% etching of the halloysite. For
the higher etched halloysite, a higher loading efficiency was obtained.
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Figure 4-13: Chlorhexidinediacetate salt hydrate release from etched halloysite.
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According to the results of drugs release from acid etched halloysite, increasing
lumen size lead to a higher loading efficiency, however the larger lumen diameter will
also cause faster leakage o f loaded substance. The fast release at a high etching
percentage also can be explained as when most o f the aluminum was reacted with acid,
the structure o f halloysite will only leave the silica base, there will be some holes
obtained on the surface o f halloysite, and the tube will become more like porous silica.
Another advantage of acid etching halloysite is that after removing some
aluminum from the inner lumen, it can decrease the positive charge. In other words,
etched halloysite may have negative charge inside the lumen. Most drugs have positive
charge, so the negative charged lumen will provide stronger absorption which will lead to
slow release.
4.3.5

Antibiotics Release from Halloysite
Antibiotics are another more specific antibacterial compounds studied for

extended efficiency due to clay nanotube encapsulation. We optimized loading and
release for two antibiotics widely used in medicine: ciprofloxacin and gentamicin. To
increase the antibiotics loading efficiency we enlarged the lumen diameter o f clay
nanotubes using acid to etch the internal aluminum layers [37].
Figure 4-14 shows loaded gentamicin release from halloysite. After 12 hours,
about 1.3 mg o f gentamicin were released from loaded halloysite, on the other hand,
loaded halloysite with stopper released

1 .1

mg gentamicin in the same time.
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Figure 4-14: Release o f gentamicin from halloysite with BTA-Cu stopper.
Figure 4-15 shows ciprofloxacin release from 35% etched halloysite and 60%
etched halloysite. The loading efficiency o f 60% etching halloysite shows

6

times higher

than in untreated halloysite. However the release o f 60% etching halloysite is faster
compare with 35% etching halloysite.
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Figure 4-15: Ciprofloxacin release from halloysite etched at different rate.
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Figure 4-16 shows ciprofloxacin release from halloysite and with BTA-Cu
stopper. Loaded ciprofloxacin released about 60% in 24 hours, and with additional
stopper, the release significantly reduced to 30% release in 24 hours.
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Figure 4-16: Release o f ciprofloxacin from halloysite with BTA-Cu stopper.
4.3.6

Antibacterial Effect o f Ciprofloxacin Loaded Halloysite
Halloysite loaded with ciprofloxacin and Halloysite loaded with ciprofloxacin

with stopper, were compared to ciprofloxacin alone in a disc diffusion assay. Total
amount o f ciprofloxacin loaded onto each disc was 5pg in all cases. Halloysite was
weighed out and diluted with sterile water for distribution onto disc. The same discs were
transferred from one plate to a fresh spread plate every 24 hours. The inhibition of
ciprofloxacin was longer when loaded into halloysite crystals. The formulation without
end stopper appeared to have a longer effect. Loaded halloysite sample still showed a
weak zone on two of the discs at 72 hours. Both halloysite formulations beat
ciprofloxacin alone in this simple test of prolonged release and inhibition o f growth.
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Loaded halloysite with stopper lost inhibition zone after 72 hours can be explained the
release amount was too less to kill bacteria.

Table 4-2: Antibacterial efficiency o f ciprofloxacin loaded halloysite (24, 48, 72
hours).In collaboration with Dr. K Lewis, Pharmacy Dep., Northeastern University.

In hib ition z o n e

In h ib ition zo n e

I n h ib itio n z o n e

24h

48h

72h

H a llo y s it e

N o inhibition

N o inhibition

N o in h ib itio n

5 p g cip r o flo x a c in

30-32 mm

N o inhibition

N o in h ib itio n

H a llo y s it e /c ip r o f lo x a c in

30-32 mm

2 0 - 2 2 mm

8-10 mm

H a llo y sit e /c ip r o f lo x a c in /s to p p e r

26-28 mm

1 6 - 2 0 mm

N o in h ib itio n

S a m p le

4.4

Conclusions

Release study and antibacterial effect of common antiseptic agent brilliant green,
iodine, amoxicillin and antibiotics ciprofloxacin and gentamicin have been studied using
halloysite clay as nanocontainers for loading and controlled release. Complete release of
non-encapsulated brilliant green occurred within 10 minutes while 70% o f this antiseptic
was released from halloysite tube lumen within 3 hours and 90% within 5 hours. Tunable
controlled release was achieved by synthesizing copper-benzotriazole complexation on
the tube surface (predominantly - at tube ends). Factors affecting release rate from such
formulations i.e. concentrations o f copper and benzotriazole used for cap formation, were
analyzed in details and optimized for the best release profile. Release rate reduces with
increased benzotriazole concentration at lower copper concentrations, which is associated
with formation o f tighter films with less porosity. However, opposite phenomenon was
observed at high Cu

2+

concentrations, which is associated with increased loading
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efficiency of the drugs. S. aureus bacterial viability assay revealed that antiseptics loaded
within halloysite lumen provided much longer activity compared to the free
microcrystals.

CHAPTER 5

SYNTHESIS OF SILVER NANORODS CORE-SHELL
STRUCTURES FOR ANTIBACTERIAL COM POSITES
5.1

Introduction

This chapter is based on my contribution to the publication titled "Natural Tubule
Clay Template Synthesis o f Silver Nanorods for Antibacterial Composite Coating", AC S
Appl. Mater. Interfaces, 2011 [46]. I am the author of this paper, and its content is used
only in my dissertation. In this chapter a method for loading silver nanorods in halloysite
is presented. Loaded halloysite with silver nanorods have unique antibacterial properties
that can be used to functionalize the nanocomposites. Also in collaboration with LSU
Dental School in New Orleans joint work will begin on artificial halloysite (loaded with
silver and antibiotics) composites for adhesive and antibacterial teeth fillings. In addition,
the synthesis metal in halloysite lumen also present potential to assisted X-ray detection
of the composites.
Metallic nanomaterials (nanoparticles, nanowires, and nanorods) have gained a
large interest in industry due to their unique physico-chemical properties resulting from
nano-confinement effects [8 6 , 87]. Different template structures (micro- and nano
containers) have been utilized for synthesizing these nanomaterials: carbon
nanotubes [88-90], porous alumina templates [91], liposomes [92], micelles [92], and
DNA [93]. The tubular templates allow for the synthesis o f internal metal nanorods
52

53

protected against surrounding environmental effects, such as oxidation or light
degradation, and provide better admixing with polymers. For instance, silver nanorods
enclosed in alumosilicate tubes may have enhanced catalytic and antimicrobial properties.
Among other nanotemplates, halloysite, naturally available aluminosilicate clay
with ca. 15 nm diameter lumen and o f 600 - 1500 nm length, can become a promising
candidate for nano-confined reactions because o f its well-defined hollow tubular structure,
abundance in nature as a raw material, and the increasing demand for environmentally
friendly products. So far, it has been used for encapsulation and sustained-release of
different chemical agents, such as proteins, drugs, antiseptics, antimicrobial agents, and
corrosion inhibitors for metal protection [19,23,26,31,84,94-96], The usage of the hollow
lumen of the nanotubes for nanoconfined enzymatic synthesis of CaCC>3 was also
demonstrated [43,97]. Clay nanotubes, therefore, offer great benefits as a template for
synthesizing metallic nanomaterials due to their appropriate lumen diameter and low cost.
In this work, we report on the selective formation o f silver nanorods within the
inner lumen o f halloysite. Our technique requires loading o f silver acetate into the tube
lumen under reduced pressure, washing, separation, and heating without any harsh
conditions or complicated steps. High-resolution transmission electron microscopy (HRTEM) and field-emission scanning electron microscopy (FE-SEM) images reveal the
formation o f silver nanorods inside the lumen as well as within some void spaces in the
tube multilayered walls. These in situ syntheses offer a simple method for fabricating
metallic nanorods and core-shell ceramic nanocomposites which can be used as well
dispersible antimicrobial additives in plastic composites [98-100], nanoelectronics [101]
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and optical materials [102-105] with additional biocompatibility and environmentally
friendliness.

5.2
5.2.1

Materials and Methods

Materials
Dehydrated halloysite clay (halloysite-7A) was obtained from Applied Minerals

Inc, NY. Silver acetate was purchased from Sigma-Aldrich, USA. Industrial oil based
blue paint on the basis o f PDS-33 powder was purchased from GPM (Cary, IL).
Escherichia coli, Staphylococcusaureus Rosenbach and Lysogeny broth were purchased
from Fischer Scientific.
5.2.2

Characterization of Halloysite
FE-SEM images were acquired using a Hitachi S-4800 FE-SEM (accelerating

voltage, 5 kV) to observe nanotube external surface morphologies. Halloysite samples
were coated with 1. 6 nm thick platinum by Cressington Sputter coater (208HR) before
each SEM experiment. TEM images were acquired using JEM-2000EX (JEOL)
microscopy (accelerating voltage, 200 kV) equipped with a CCD camera. HAADFSTEM (High Angle Annular Dark Field - Scanning Transmission Electron Microscopy)
and EDS-STEM (Energy-Dispersive X-ray Spectroscopy - STEM) analyses were carried
out using JEM-2100 (JEOL) microscopy (accelerating voltage, 200 kV). A suspension o f
halloysite samples in distilled water (0 . 2 wt%) was sonicated for 2 hrs and the solution
was settled for 4 hrs. The supernatant o f the halloysite solution (2 gl) was spotted on a
copper TEM grid covered by an elastic carbon-support film with a filter paper
underneath, and excess solution was blotted immediately with filter paper. The TEM grid
was dried under a reduced pressure overnight before observation. No coating or staining
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was applied for TEM observation. Nitrogen BET adsorption isotherms were obtained
with Nova 2000, Quantochrome Instruments. Halloysite samples were degassed in a
vacuum at 300 °C before each BET absorption measurement. An X-ray powder
diffractometer (Bruker-D 8 Discover, Cu Ka radiation 0.154 nm) was used for the crystal
analysis. Light microscope (Olympus, Japan) with video camera (Sony SSC DC 80) was
used to analyze paint samples.
5.2.3

Synthesis of Silver Nanorods
Halloysite (5 mg) and silver acetate (10 mg) were added into deionized water

(10 ml) and the suspension was immersed into a vacuum for 30 min. Loading of silver
acetate was achieved by pulling and breaking vacuum three times. After the loading
procedure, halloysite was washed, separated by centrifugation, dried at 80 °C for about
3 hrs, and heated at 300 °C for 1.5 hrs to decompose silver acetate into silver nanorods.
5.2.4

Kinetics of Silver Acetate Decomposition
Dried and grinded halloysite loaded with silver acetate was placed on an Isotemp

hot plate at 300 °C. Samples were collected at certain time intervals, dispersed in DI
water and sonicated for

1 0

min (water was bubbled with nitrogen for

2 0

minutes to

remove dissolved oxygen). Then copper strips were inserted into the solution causing
reduction of non-decomposed Ag+ salt (or Ag 2 0 ) present in the sample. The quantity o f
silver ions were calculated by measuring the concentration of Cu(I) ions released into
water due to the oxidation o f metallic copper with Ag+ ions. Cu(I) were further oxidized
to Cu(II) ions by hydrogen peroxide and detected with UV-Vis spectrophotometry using
sodium diethyldithiocarbamate.
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5.2.5

Halloysite Based Antimicrobial Paint
Antimicrobial paint was prepared by the addition of 10% of halloysite silver

composite into blue oil based paint and mixed by means of simple mechanical mixing. A
sample was applied to thin aluminum foil and dried for 4 days. Then the paint was
released by etching the foil in 0.5 M NaOH solution and dried 1 more day. The original
paint was released in a similar way.
In order to test antimicrobial properties, 15 g/L solutions of Lysogeny broth (LB)
and LB agar in DI water was prepared and sterilized at 121 °C for 15 minutes. LB agar
was poured into Petri plates after sterilization and cooled down. Two kinds o f bacteria,
gram-negative Escherichia coli and gram-positive Staphylococcusaureus Rosenbach,
were cultured at 37 °C overnight and dissolved separately in 3 ml of LB solution and
again stored at 37 °C overnight. 100 microliters o f this solution was spread over the
plates by using glass beads and dry pieces of paint samples were carefully placed in the
bacteria culture. Samples were stored at 37 °C. After one week samples were analyzed
with Light Microscope to observe bacteria growth around the paint.
5.2.6

Halloysite/Paint Mechanical Property Test
Stress-strain curves o f the paint samples were obtained by using an ADMET

tensile tester (EP-0801161-M-48VAC). Dimensions o f the paint film samples were
5.5±0.5 mm in width, 13.0±0.5 mm in length, and o f 0.25±0.04 mm thicknesses. Samples
were pulled with the speed o f 0.3 mm/min for obtaining a stress - strain curve. Impact
strength o f the paint was tested by applying it onto 1 mm thick iron plates (A366 Iron
alloy). Samples were dried for 1 week and then subjected to the rapid deformation by
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dropping 0.2 kg iron bar on the back sides of the paint. Paint was analyzed with a light
microscope for the formation of cracks.

5.3
5.3.1

Results and Discussion

Silver Nanorods
Silver nanorods were selectively synthesized within the halloysite inner lumen via

the loading o f silver acetate from aqueous solution. In this one-step facile method, the
aqueous suspension o f halloysite containing silver acetate was first degassed under
vacuum, followed by loading of silver acetate, which was carried out by pulling and
breaking vacuum. After washing and drying, the silver nanorods in the halloysite
nanotubes were formed on heating at 300 °C for 1.5 hrs to reduce the silver ions
(Figure5-1).

halloysite
lo a d in g of silver
acetate

si l v e r n a n o r o d s
in h a ll o y s i t e

Figure 5-1: Schematic illustration of the synthesis o f silver nanorods within the halloysite
inner lumen: suspension o f halloysite and silver acetate in water; loading o f silver
acetate; formation of silver nanorods within halloysite templates on heating [46].
Formation o f silver nanorods takes place in two steps; decomposition o f silver
acetate into tiny silver nanocrystals within halloysite pores, and growth of these
nanocrystals into nanorods. The first process takes place at lower temperature (~ 280 °C)
followed by the second process (~ 290-300 °C). Figure 5-2 a shows STEM images of
silver nanorods within halloysite tubular templates, exhibiting unbroken silver nanorods

extended along the tube lumen. Its diameter corresponds to the lumen diameter of
15±2 nm and the length is of several hundred nanometers. Sizes of the silver
nanoparticles and nanorods are smaller than the data observed by Logvinenko,
et al. [106] during thermal decomposition of free silver acetate. We assume that
crystalline defects on halloysite facilitate formation of smaller silver nanocrystals and
their growth is limited by the tube lumen size. Silver nanorods were effectively
encapsulated by the halloysite tubes allowing the formation o f a metal core with
insulating alumosilicate shell. This insulation protects the silver nanorods from the effects
o f the external environment containing oxygen and light.
Besides the nanorods synthesized in the tube lumen, minor quantities o f silver
were deposited into the interlayer space and in external tube defects. One can see the
linear arrangements o f such silver nanoparticles and the parallel orientation of smaller
silver rods (Figure 5-2 b-d).
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Figure 5-2: (a, b) HAADF-STEM and (c, d) HR-TEM images of silver nanorods within
halloysite tubular templates [46].
The arrangement o f the silver nanoparticles along the tubes clearly indicates the
presence of linear defects on the halloysite external surface. This observation is in
accordance with the expectation that the vacancies on the layers may produce localized
negative charges resulting from the missing o f SiIV, which attract positively charged Ag+
ions and their reduction to the silver nanoparticles and nanorods along the defect. The
presence o f localized linear defects on the surface o f the halloysite tubes was also
suggested by Kirkman [108]. Using the crystal dislocations theory, he assumed that the
linear arrangement o f the vacancies on the halloysite external surface is responsible for
the rolling o f aluminosilicate layers, and this was supported by the presence of kinks on
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the halloysite outermost layers. Despite the formation o f silver nanoparticles in the
halloysite voids, their coagulation to larger particles was hindered because o f the
confined internal space.
5.3.2

Spectral Analysis of Elemental Composition and Crystalline Structure
Figure 5-3 (a) gives the results for the energy dispersive X-ray spectroscopy

(EDS) elemental analysis o f the silver-halloysite nanocomposites. Signals from silver
(Ag) are clearly visible for L-a (3.0 keV) and L~p (3.2 keV) spectral lines. Concentration
o f silver is 6±3 atomic %. Signals from copper (Cu) arises from the TEM grid. Signals
from oxygen, aluminum and silicon, the main constituents o f the halloysite nanotubes,
are also presented. Small amounts of Na are present in the halloysite sample as an
impurity. Na and Ca based impurities increase the cation exchange capacity (CEC) o f the
halloysite which is related with the quantity o f the vacancies [107],
Figure 5-3 b gives the XRD profile o f the silver nanorods formed in the halloysite
clay tubes. Picks corresponding to the (111), (200), (220), and (311) planes of Ag are
clearly visible, which proves silver is in crystalline form. Reflections at the scattering
angles below 38° are from halloysite clay and overlapped with (100) Ag peak. Peaks at
45 - 65° range are from clay impurities (quartz, alunite). Smaller intensity o f the silver
peaks in the XRD spectra is associated with a smaller concentration o f the metallic silver
present in the sample. Partial oxidation o f silver to Ag20 is also probable.
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Figure 5-3: (a) EDS elemental analysis of the silver nanorods loaded in the halloysite
nanotubes, (b)XRD profile o f silver nanorods encased in halloysite tubes [46],
5-3.3

Kinetics of Silver Acetate Thermal Decomposition
Silver nanorods and nanoparticles are synthesized in the halloysite lumen by

thermal decomposition of loaded silver acetate. The original white sample was gradually
turning into a dark silvery color during the reaction. Figure 5-4 a, b gives the UV spectra
of the reaction mixtures taken at different time intervals and the decomposition kinetics.
The absorption at 445 nm is constantly decreasing with time indicating the thermal
decomposition o f the silver acetate into metallic silver.
Decomposition took ca 30 min and follows the first order reaction kinetics with
the rate constant of 0.183 m in'1 at 300 °C.
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Figure 5-4: (a) UV spectra o f the silver acetate decomposition on halloysite nanotubes
taken at different time intervals, (b) silver acetate decomposition kinetics [46].
5.3.4

Elemental Mapping
To study the elemental composition throughout the core-shell nanostructures, a

detailed chemical analysis was carried out using EDS mapping. The elemental maps
displayed in Figure 5-5 give the distribution of the constituent elements, that is, Si, Al,
and Ag. Signals from silver are located in the tube interior whereas silicon and aluminum
mappings show their elemental distribution along the entire tube body. The halloysite
empty lumen confined the volume available for the crystallization of silver leading to
nanorod formation. The diameter o f the rods coincides with the diameter o f the inner
lumen which is 15±2 nm.

Figure 5-5: STEM images of silver nanorods loaded in the halloysite nanotubes (a, b) and
corresponding EDX mapping of Ag (c, d) [46],
5.3.5

TEM Observations o f Silver Crystalline Structure
To further describe the crystalline structure of the silver nanorods, samples were

analyzed with High Resolution Transmission Electron Microscope. Figure 5-6 shows
HR-TEM images o f silver nanorods in the halloysite nanotubes. The lattice fringes are
clearly visible in the magnified image (Figure 5-6 b), indicating the monocrystalline
silver nanorods. Periodicity of the lattice is approximately 0.32±0.02 nm which coincides
with (111) i/-spacing o f the silver crystal. Interestingly, the lattice plane is oriented at
68±3° toward the halloysite tubule axis which corresponds to the orientation o f (111)
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plane toward the (100) plane alined along the tube. The crystal structure of silver in the
halloysite nanotubes was also verified by powder X-ray diffraction analysis (Figure 5-3).

Figure 5-6: HR-TEM images of silver nanorods synthesized by thermal reduction of
silver acetate loaded in the halloysite lumen [46].
5.3.6

Sliver Nanoparticle on Halloysite External Surface
We also can get many silver nanoparticles synthesized on the external surface o f

halloysite by skipping the wash step. Since Ag ion is positively charged, it will be
attracted by the negatively charged halloysite external surface (Si). After the vacuum
loading method, if we skip the wash step, some Ag ions absorb on the external surface of
the halloysite. After heating at 300 °C, these Ag ions will form silver nanoparticles on the
halloysite external surface (Figure 5-7).

Figure 5-7: Sliver nanoparticle on halloysite external surface.
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5.3.7

Antimicrobial Coatings with Silver Loaded Halloysite Nanotubes
Nowadays paint products contain a lot o f additives including nanoparticles, such

as titanium dioxide, silica, clay, mica, and latex. Silver based composite particles can be
applied as an antimicrobial additive to prevent bacterial corrosion [105,109-112]. A
direct addition of the silver compounds to the paint has some disadvantages. Paint
samples with silver based additives acquire a characteristic yellow —brown color due to
the decomposition of silver compounds into silver nanoparticles, which is not desirable
(Figure 5-8 and Figure 5-9). Besides, silver nanoparticles absorb UV light and emit
plasmons which enhance polymer degradation. In our core-shell structures, encased silver
nanorods are better mixable with polymers than individual silver nanoparticles. As
demonstrated in Figure 5-8 and Figure 5-9, the color o f our coating doped with core-shell
silver nanorods was preserved.

Figure 5-8: Images o f acrylic latex paint after one week light exposure: (a)-original paint,
(b) doped with 5 wt% halloysite-silver composite, (c) with 5 wt% silver oxide and (d)
with 5 wt% silver nitrate 20-40 nm diameter nanoparticles.
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Figure 5-9: Images o f epoxy paint after one week light exposure: (a)-original paint (b)
doped with 5 wt% halloysite-silver composite, (c) with 5 wt% silver oxide and (d) with
5 wt% silver nitrate 20-40 nm diameter nanoparticles.
An incorporation o f silver nanoparticles into halloysite tubes also extended
lifetime o f the antimicrobial effect. In Figure 5-10, images o f the polymer based metal
coatings and their composites with halloysite tubes are shown after one week o f exposure
to E. coli and S. aureus bacterial cultures. Bacteria grow rapidly in the regions around the
original paint without halloysite-silver additives. The edges o f the paint samples are not
clear in Figure 5-10 (a), (c) indicating that some bacteria was growing on the surface of
the paint. A significant amount o f bacteria was growing underneath the paint, also
indicating bacterial inhibition. Silver nanorod loaded halloysite doped in the paint
significantly inhibited bacterial growth. Ag+ ions slowly leak from the tubes and inhibit
bacterial growth on the paint surface, and additionally a clear zone o f inhibition at the
paint edge, were observed in both the cases (Figure 5-10 (b), (d)).
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Figure 5-10: Images o f the original paint samples (left) and paint prepared by addition of
5 wt% halloysite nanotubes with silver nanorods (right) after one week o f exposure to E.
coli (a, b) and S. aureus (c, d) [46].
Antimicrobial activities o f silver-halloysite composites are related with the
amount o f silver ions released: 10 mg/ml o f halloysite-silver nanocomposites releases
approximately 1 mM o f silver ions to the aqueous environment (Figure 5-11). It is 5
times more than the corresponding data for the silver oxide doped bioactive glass
nanoparticles [113] and 20 times more than the corresponding data for silver doped
carbon nanotubes [109]. Higher release o f silver ions is related with the higher
concentration o f silver in the nanocomposite (Ag : Si ratio is 0.30 in our case vs 0.023
reported by Kawashita, et al. [110-111] for silver-containing silica particles).
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Figure 5-11: Silver ion release kinetics from halloysite-silver composites.
Larger zone o f inhibition was observed around the cracks in the paint
(Figure 5-12 a). This is assumed to be an indication o f halloysite nanotube openings in
the cracks. Tubes are exposed to the external environment in the cracks thus enhancing
the leakage o f Ag+ ions, which kills bacteria and preventing biocorrosion.

I*

Figure 5-12: Inhibition area around the cracks in the paint (a) and a representative SEM
image o f the halloysite tubes at the paint cracked surface (b) [46].
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5.3.8

Hallovsite/Paint Composite Mechanical Property
In Figure 5-13(a), the stress-strain relationship o f the oil based blue paint and

halloysite - paint composite is shown. Addition of 5-10 wt% o f the halloysite
significantly increased the tensile strength o f the paint. The halloysite - paint composite
also shows better performance towards rapid deformation, as demonstrated in
Figure 5-13(b), (c). A 0.2 kg metal bar was dropped on the painted iron plates (on the
basis of A366 alloy) from the height of 1 m in order to subject the plates to rapid
deformations. The thickness of the metal plate was 1 mm in both cases. As indicated in
the picture, the metal coated with pure paint has a lot of cracks in it due to the rapid
deformation o f the plate, while the same paint containing 10 wt% halloysite did not show
any evidence o f the cracking.

• P aint w ith 10% h*Boy*it»
a Pare P aint

Figure 5-13: Mechanical properties of pure paint and halloysite paint nanocomposite (a).
Stress-strain relationship and images o f the pure paint (b) and 10 wt% halloysite-paint
composite (c) after rapid deformation test [46].
5.4

Conclusions

We reported syntheses o f silver nanorods using halloysite nanotubes as a template
created by this metal-ceramic core-shell nanocomposite. The growth of single crystal
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silver nanorods with 15 nm diameter in the clay tube lumens has been demonstrated.
Some nanoparticles were also formed in the nanotube defects caused by the presence o f
vacancies in the tubes (voids within the multilayer walls). An addition into the paint o f
5 wt% o f such silver nanorods encased in clay tubular shells resulted in the composite
antimicrobial properties with synergistic enhancement of the coatings tensile strength and
preservation of the coating color even after strong light exposure. These core-shell silver
nanorods can be used as antimicrobial additives for polymer composites and paints.
Halloysite is a cheap natural tubule nanomaterial which has a good potential for scalable
manufacturing of metal nanorods.

CH APTER 6

HALLOYSITE NANOTUBES COM POSITES FOR BONE CEM ENT
WITH CONTROLLED RELEASE OF ANTIBIOTICS
6.1

Introduction

This chapter is based on my contribution to the publication titled "Clay
Nanotube/Polymethylmethacrylate Bone Cement Composites with Sustained Antibiotic
Release." Macromol Mater Engineering, 2012 [83], I am the first author of this paper and
its content is used in the following Chapter six with proper referencing. This material is
not used in any other PhD or MS theses produced in our research group. In this research
we expanded our results for drug loading and sustained release with clay nanotubes by
doping drug loaded tubes into bone cements. With this method, we improved the
polymethylmethacrylate (PMMA) and calcium phosphate bone cements traditionally
used in orthopedic surgery with new properties (enhanced strength, adhesivity and
antimicrobial efficiency).
Polymethylmethacrylate (PMMA) bone cement has been used in orthopedic
surgeries since 1958 [3]. Its biocompatibility and mechanical properties have made it a
remarkable and indispensable tool in orthopedic repair, specifically in joint replacement
arthroplasty. The two-stage knee arthroplasty revision for infection, with implant removal
and interval o f antibiotic therapy before implant replacement, was invented later and is a
standard clinical procedure [4], Antibiotics were added to bone cement to improve local
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antibiotic delivery in addition to intravenous doses [3, 7]. This practice has improved
implant survival and reduced reinfection rates. The non-porous PMMA bone cement
allows for release of only a portion of the antibiotics evenly distributed throughout the
cement [8]. Current cement formulations release less than 3% of the total loaded
gentamicin sulfate during the first ten days, with at least 70% of that released within the
first 24 hours [5,6,9]. PMMA’s material strength is also compromised by cement
additives, though there has been recent development o f PMMA - montmorillonite
composites that promote greater antibiotic elution and enhanced material strength [114].
The development goals o f these PMMA composites are increased efficient and sustained
release o f antibiotics without compromising implant strength.
Encapsulation of antibiotics, particularly within micro- and nano-scale containers,
has the potential for prolonged and more evenly distributed release. One such container is
halloysite clay nanotubes which are described in Chapter 2. Halloysite nanotubes loaded
with tetracycline were also incorporated in dental fillings in a canine model [82], In
addition to the potential for sustained release, admixed halloysite also enhances polymer
and epoxy physical properties [117]. An attractive aspect of halloysite nanotubes is that it
is economically viable. Halloysite’s particle size is not in the range where silicosis or
asbestosis related complications would occur [34],
In this study, we used clay tubule nanocontainers to produce PMMA
cement/halloysite nanocomposites with the properties o f sustained drug release and
without compromising bone cement strength. Enhancement o f the composite
adhesiveness to bone over PMMA alone was also shown.
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6.2
6.2.1

Materials and Methods

Materials
Polymethylmethacrylate (PMMA) bone cement, Orthoset-3, was kindly provided

by Wright Medical Technologies (Arlington, TN). Halloysite nanotubes were provided
by Applied Minerals, Inc. (New York, NY). Gentamicin sulfate was purchased from
Cellgro by Mediatech, Inc. (Manassas, VA).
6.2.2

Loading Antibiotics in Halloysite Lumen
Powdered halloysite was added to a concentrated aqueous solution o f gentamicin

sulfate (50 mg/ml). The suspension was then sonicated for 2 hours, followed by 20
minutes in a vacuum at 100 torr to draw the drug into the tubes. Vacuuming was done in
three intervals with 20 min at atmospheric pressure between each vacuum processing
step. Samples were then briefly washed to remove gentamicin associated with the outside
surface o f halloysite. After centrifugation, the supernatant was removed and the
remaining samples were placed in an oven to dry at 55 °C for two hours. Typically, 10
tol5 wt% loading of halloysite with gentamicin was achieved. For some experiments,
loaded halloysite was used without washing for testing with gentamicin also bound to the
outside of the tube.
6.2.3

Gentamicin Release
Drug release experiments were conducted by putting samples in deionized water

(DI). At each reading, the DI water was removed and replaced with fresh DI water.
Because gentamicin does not have UV signal, equal parts liquid sample, isopropanol, and
o-phthaldialdehyde solution were mix together and allowed to sit at room temperature for
30 minutes. With an Agilent-8453 UV-vis spectrophotometer, the mixture absorbency
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was monitored at the 331 nm wavelength. O-phthaldialdehyde solution was made by
adding 2.5 g o-phthaldialdehyde, 62.5 ml methanol, 3 ml p-mercaptoethanol (SigmaAldrich, St. Louis), and 560 ml 0.04 M sodium borate. The solution was then allowed to
sit at room temperature for 24 hrs before usage (solution was then used within 72 hrs).
6.2.4

Tensile, Flexural and Adhesion Tests
A tensile tester (ADMET Corp., EP-0801161-M-48VAC) was used to test the

samples’ tensile and flexural strength. All the samples were made in a standard bone
shape (the center section is 3 cm xl cmx0.5 cm) and kept in DI water to allow the leakage
o f gentamicin. This treatment with water allows the consideration o f the effect of
surrounding body fluids to the mechanical properties o f the implants after long time
exposure.
Adhesion o f bone to cement was assessed using cow femurs (obtained from
Louisiana Tech’s Meat Processing Plant). Adhesion was tested using two standard
methods (ASTM D5178 and D4541 standards). The surfaces of the bones were cleaned
before every test with ethanol. In the first test, cement was applied to two pieces o f flat
bone with grooves on the surface to combine perpendicular and tangential adhesion
properties (interface area was 0.8 cm x0.8 cm). Then the bones were pulled apart, and the
force required to break the sample was registered. The fractured interface was analyzed
with a light microscope (Olympus, Japan). For the second adhesion test, cement was
coated on the surface o f the bone (area 1.0 cmx 1.0 cm). The maximum peel force
required to remove the cement layer from the bone was measured.
Adhesion strength on a titanium implant was assessed by cutting the titanium
implant and choosing the top part which has a cylindrical geometry. Glue
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PMMA/halloysite bone cement on the cylinder titanium implant as a ring structure (width
o f the ring composite is 15 mm; the thickness of the ring composite is 3 mm). We drill a
hole on the metal plate, the diameter o f the hole is equal to the diameter of the cylindrical
titanium implant in which the implant can go through the hole but the cement ring cannot.
Then, using the tensile strength machine to pull the implant through the hole o f the metal
plate to separate the implant and the bone cement, we measure the maximum force
needed.
Halloysite/glue composite flexural strength was assessed by mixing thoroughly a
certain amount o f halloysite with glues for making composites. Using the composite glue
to connect two pieces o f ceramic, and using pure glues to connect another two pieces to
be the control. Let all samples dry at room temperature for 24 hours. The ADMET tensile
strength machine will be used to measure the flexural strength of all samples.
6-2.5

Structural Analysis
SEM images o f the broken sample sections coated with 0.5 nm o f gold were

obtained with a Hitachi Field Emission Scanning Electron Microscope. Transmission
electron microscopy (TEM) was done with the help o f JEM-2000EX instrument, Japan.
Halloysite X-ray diffraction analysis was performed with XRD, Bruker-D8 Discover
instrument, Cu Ka radiation X = 0.154 nm. Brunauer-Emmett-Teller (BET) surface area
o f the samples was measured with the nitrogen Quantochrome Inst., NOVA 2200.
6.2.6

Statistical Analysis
Statistical evaluation was performed by using Student’s t test:

t = \x —fi0\ /( s /y fv ) , where / is the Student's t-functional and corresponds to 2.92 in our
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case (degree o f freedom=2 and 90% probability), x is the sample mean, p 0 the true
mean, s the standard deviation of the sample, and n is the sample size.
6.2.7

Antibacterial Tests
Escherichia coli and Staphylococcus aureus were used for the antibacterial test of

PMMA/halloysite/gentamicin composites. We used four samples: pure PMMA cement,
PMMA cement with 1 wt% free gentamicin, PMMA with 7.5 wt% unloaded empty
halloysite and PMMA with 7.5 wt% gentamicin loaded halloysite. Each sample was
placed in E. coli and S. aureus cell cultures for 7 days, and digital images of the bacterial
colony development were then taken.

6.3
6-3.1

Results and Discussion

Hallovsite-PMMA Composite Structure
Bone cement samples were prepared by free radical polymerization of

methylmethacrylate (MMA) with benzoyl peroxide following a standard procedure
recommended by the manufacturer. A dry mass containing the benzoyl peroxide and
partially polymerized MMA was thoroughly mixed with liquid MMA (2:1 mass ratio)
and left for 10 minutes for complete polymerization.
Halloysite-PMMA composites were prepared using halloysite admixed dry
powder instead o f the original commercial sample. Figure 6-1 shows images of the
PMMA/halloysite samples. Original PMMA cement has a white color that turns creamy
yellow upon the addition o f halloysite. Addition o f free gentamicin did not have an effect
on the color o f the cement composite.
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Figure 6-1: Images of PMMA bone cement (a) and PMMA/halloysite composites with
5 wt% (b), 7.5 wt% (c) and 10 wt% (d) halloysite [83],
Figure 6-2 shows the SEM images o f PMMA bone cement/halloysite composites.
The addition o f 5 wt% halloysite into PMMA cement gives a good distribution of clay
nanotubes within the polymer matrix (Figure 6-2 b). However, particles were
significantly aggregated in the PMMA samples with 10 wt% halloysite (Figure 6-2 d).

Figure 6-2: Cross-sectional SEM image o f PMMA (a) PMMA/halloysite composites
doped with 5 wt% halloysite (b), 7.5 wt% halloysite (c) 10 wt% halloysite (d).
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6.3.2

Mechanical Properties o f Halloysite-PMMA Composites
The mechanical strength and adhesion of bone cement are crucial for the success

of joint replacements as bone cement is the weakest mechanical link in such a
construction, and this is likely to be a factor in the loosening o f the prosthetic
device [118]. Therefore, it is important to assess the influence of the additives to PMMA
on the mechanical and adhesive properties o f the final composite material. We used seven
samples with different percent combinations of halloysite and gentamicin in order to
analyze the influence o f these combinations individually. Halloysite nanotubes were
loaded with gentamicin in all cases. Samples were kept in water for 50 days and wetted
before tests in order to mimic the effect of the surrounding in-vivo interstitial fluid
environment on the mechanical properties o f the cement.
6.3.3

Tensile Strength o f PMMA/Hallovsite Composite
The ADMET tensile tester was used to determine the strength o f the dog bone

shaped PMMA/halloysite composites. Samples were prepared according to ISO-527
standard and pulled with the speed o f 0.02 mm/sec until their failure. Stress and strain
generated in the samples are calculated from the formula [26]:
Strain(o) = AL/L0 x 100; Stress(e) = F /(w x t)

(1)

Where, Lo is the original length of the sample, F is the force loaded on the
sample, w is the width of the sample, and t is the thickness of the sample.
Figure 6-3 shows tensile strength results o f the PMMA / halloysite composite
samples. Tensile strength o f the composites increased from 18.0 MPa to 26.1 MPa when
5 wt% halloysite was added (ends o f the blue and pink lines). Tensile strength slightly
decreased when the amount of the halloysite exceeded 10 wt% but it was still higher than
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original PMMA cement. The tensile modulus of the composite did not change
significantly.
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Figure 6-3: Tensile strength of the PMMA / halloysite composites.
Table 6-1 shows the results o f the tensile testing based on the average o f three
experiments. We compared the results for original PMMA cement, PMMA cement doped
with gentamicin loaded halloysite nanotubes, and PMMA cement loaded with both
halloysite nanotubes and the addition o f traditional 1.5 wt% admixing o f free gentamicin
into the cement monomers before polymerization. Samples containing 5 wt% halloysite
had the maximum strength and exceeded the strength of pure PMMA cement and PMMA
cement loaded with free gentamicin (addition of 1.5 wt% o f free gentamicin reduced the
strength o f the samples).
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Table 6-1 Mechanical and adhesive properties of PMMA / halloysite composites.
Peak
Flexural
Max force at
Tensile
stress
Strength
balanced beam
Modulus
(MPa)
adhesion test (N)
(MPa)
(GPa)
Original PMMA
39±2
28±13
21 ±3
0.25±0.03
Samples doped with loaded halloysite, without free gentamicin
PMMA + 5%
35±2
103±15
0.24±0.02
29±1
halloysite
20±4
123±22
PMMA + 7.5%
0.23±0.02
31±1
halloysite
24±2
187±23
PMMA + 10%
19±7
0.26±0.03
halloysite
Samples doped with loaded halloysite + added 1.5% o f free gentamicin
PMMA + 5%
26±1
0.21±0.02
32±1
99±16
halloysite
PMMA + 7.5%
24±4
27±1
159±46
0.23±0.02
halloysite
PMMA + 10%
0.26±0.03
28±2
222±27
20±7
halloysite

6.3.4

Flexural Strength o f PMMA/Hallovsite Composite
A three point bending model was used to measure the flexural strength. All

PMMA/halloysite composites were made into a rectangular shape with dimensions of
3 cmxl cmx0.5 cm. Flexural stress and strain was calculated from the formula:
S tress(a) = 3 P L /2 w t2 ; Strain(e) = 6 td /L 2

(2)

Where, P is the load at a given point on the load deflection curve, L is the length
o f support span, w is the width, t is the thickness o f the sample, and d is the beam
deflection at the center.
Maximum flexural strength was observed for the original PMMA sample and was
decreasing from 41 MPa to 27 MPa upon addition o f 10 wt% of halloysite suggesting that
samples become more brittle with the addition of halloysite. Results presented in

Table 6-1 also support this conclusion. The addition of 1.5 wt% of free gentamicin
slightly reduced the strength of the samples.
Considering the mechanical properties o f the PMMA/halloysite composites,
optimal doping of the halloysite is 5 wt% which gives both higher tensile strength and
good flexural properties. Halloysite was loaded with ca 15 wt% of gentamicin, which
means that 5 wt% halloysite doping provides 0.75 wt% gentamicin concentration in the
composite. In some cases, it is reasonable to have a combination of traditional 1.5 wt%
gentamicin admixing in MMA monomers before cement solidification plus doping with
gentamicin loaded halloysite, which provides for combined release o f the antibiotic in the
bone implant. Strength parameters of such composites were also improved and are shown
in the bottom section o f Table 6-1.
It is interesting to compare our results with other PMMA bone cement composites
with added nano and microparticles. Gomoll, et al. [119] showed that the addition of
1-3 pm diameter barium sulfate microparticles decreased by 40% the composite tensile
strength. However, a smaller 100 nm particle diameter allowed restoration o f the initial
PMMA cement strength and increasing its fatigue life. Our halloysite nanofiller increases
the tensile strength of the composite and, as it will be shown below also increased its
adhesivity.
6.3.5

Adhesion o f PMMA/Hallovsite Composites to Bone Surface
The adhesive force between PMMA/halloysite composites and bone surfaces was

tested in bovine femoral bone, since most o f the failures occur at the PMMA/bone
interface. There are many different methods for the testing o f adhesion and all o f them
have certain limitations. In this study, we used a tensile tester to demonstrate the effect of
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the addition o f halloysite on PMMA adhesion to a bone surface. For this test, we glued
two pieces o f bone samples to each other with the PMMA sample and pulled them apart
to determine the maximum force.
In Figure 6-4, images of the bone-PMMA interface, after being pulled apart with
the tensile tester, are shown. An SEM image o f the bovine femoral bone surface is also
shown. The bone has pores with a diameter o f ca 200 nm. Three samples o f PMMA
cement: original (without additives), with 1.5 wt% of free gentamicin and with 7.5 wt%
o f halloysite loaded with gentamicin were used as connecting glue (total amount of
gentamicin available for release from both cement samples was equal to 1.5 wt%). The
purpose of this test was to show the efficiency o f using gentamicin loaded halloysite
instead o f free gentamicin as an additive in PMMA to get the equivalent antibacterial
properties without loss o f structural integrity. These images clearly indicate that the
PMMA composite with 7.5 wt% halloysite loaded with gentamicin has significantly
increased adhesion to the bone surface compared with the original PMMA sample and
the sample with 1.5 wt% o f free gentamicin. For the PMMA/halloysite composite
connector, failures occurred within the bone whereas it occurred at the cement-bone
interface with the other two samples. These data suggest that the PMMA / halloysite
nanocomposite provides greater adhesion to bone compared with the original PMMA
sample and the 1.5 wt% free gentamicin sample. The force required to break
nanocomposite samples was 500±20 N, original PMMA cement sample
was290±20 N,and the sample with free gentamicin loaded was 280±80 N (average of
three experiments). This result suggests that using gentamicin loaded halloysite instead of

83

free gentamicin as a filler in PMMA bone cement has a major advantage in terms o f its
adhesive properties.

Figure 6-4: Images at PMMA composites - bone interface after fracturing with tensile
tester. Original PMMA (a) 1.5 wt% gentamicin-PMMA (b) 7.5 wt% halloysite-PMMA,
and (c) SEM o f cow femur bone structure (d) [83].
In order to characterize the increase in adhesive properties with the addition of
halloysite into bone cement, we used the balanced beam adhesion test (ASTM D5178
standard method), since it provides the best method for analyzing the adhesion between
two hard (non-deformable) solid materials [120]. In Figure 6-5, a simplified sketch of the
apparatus used for testing the adhesive force between PMMA and the bone samples is
shown. The device contains a beam with a movable cantilever that pushes the samples
attached to the surface once a load is applied to the end o f the beam. In order to get more
precise results, we slightly modified the industrially available balanced beam adhesion
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tester and attached it to the tensile tester to measure the load applied to the end of the
beam. With simple calculations, we found the relation between the force applied to the
PMMA sample and the load applied to the beam as follows:
F = (P + b)L/ a x (ctg(p) - p)

(3)

Where, F is the force applied to the PMMA sample; P is the load on the end of
the beam; a and L are dimensions o f the apparatus; b is the weight o f the beam; ctg(ff) is
the cotangent o f the beam inclination angle (p) and // is the friction force between the
cantilever tip and the bone surface. For simplicity we considered p = 0 since the friction
force was negligible compared to the adhesion force between PMMA and the bone
surface. One can see that an almost six times larger force is needed to detach the cement
composite doped with 10 wt% halloysite as compared to the original PMMA cement
(Figure 6-5 b).
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Figure 6-5: Simplified sketch o f the apparatus for testing the adhesive forces between the
PMMA bone cement and cow femur bone (a), and the maximal force needed to detach
the cement depending on the halloysite doping ratio(b) [83],
The maximum force required to remove the PMMA cement layer from the cow
femur bone is shown in Table 6-1 for PMMA bone cements with different amounts of
added halloysite. The force increased five times when PMMA doped with 7.5 wt%
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halloysite (which is considered as the optimal in view o f different strength parameters),
and continues to increase monotonically with the increase o f the halloysite concentration.
The addition o f free gentamicin did not significantly affect the adhesion between the
PMMA cement and bone surface.
6.3.6

Adhesion of PMMA/Halloysite Composites to Titanium Implant
Based on our previous research on PMMA/halloysite composite results, the

composites shows improved adhesive ability on the bone surface. The next step is to find
out if the PMMA/halloysite composite can also improve adhesive ability on the implant
surface. In this research we choose a titanium implant (Figure 6-6).

Titanium im plant

M etal p late
HNTs/PMMA c o m p o s ite

Figure 6-6: (a) Titanium implant (b) SEM of titanium implant surface (c) Simplified
sketch of the apparatus for testing the adhesive forces between the PMMA bone cement
and titanium implant.
5 samples are made: PMMA with 0 wt% halloysite, PMMA with 5 wt%
halloysite, PMMA with 7.5 wt% halloysite, PMMA with 10 wt% halloysite, and PMMA
with 1.5 wt% gentamicin.
Figure 6-7 shows that after halloysite is added into the PMMA bone cement, the
maximum force needed to remove the PMMA/halloysite composite decreases from
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640±20 N (0 wt% HNTs) to 600±20 N (5 wt% HNTs) and 610±20 N (7.5 wt% HNTs),
respectively. However, the maximum force o f the composite with 10 wt% HNTs
increased to 760 ±20 N. On the other hand, PMMA bone cement mixed with 1.5wt %
gentamicin also shows that the gentamicin has almost no influence on PMMA bone
cement adhesion on a titanium implant.
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Figure 6-7: The maximal force needed to detach the cement from titanium implant
depending on the halloysite doping ratio.
6.3.7

PMMA/Halloysite Composite Hydrophobicity
In Figure 6-8, the water contact angle measurements for the PMMA bone cement

samples are presented. One can see that the contact angle is slightly reduced upon the
addition of halloysite into PMMA (from 64.3° to 54.9°). This suggests that the moderate
increase of the hydrophilic forces between PMMA and bone surface upon addition o f
halloysite is only partially responsible for the observed large increase in adhesion force.
The second reason for the drastic increase o f halloysite composite adhesiveness may be
related to the intercalation of the needle-like clay nanotubes into the porous bone surface
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(Figure 6-4 d). Halloysite nanotubes o f 50-100 nm in diameter can easily penetrate into
100-300 nm size pores at the bone surface and cause anchoring which increases the
resistance towards the external shear forces.

5% h a llo y s ite - P M M A
c o m p o s i t e 6 6 .3 1 5 °

7 .5 % h a llo y s it e - P M M A

1 0 % h a l lo y s i te - P M M A

c o m p o s i t e 5 2 .9 ± 5

c o m p o s ite 5 4 .9 1 5 !

P M M A + 1 .5 %
g e n t a m i c i n 6 8 .7 1 5 °

Figure 6-8: Water contact angle changes after halloysite is added into the PMMA bone
cement [83].
6.3.8

Adding Halloysite into Glue to Enhance Adhesive Property
Based on our PMMA/halloysite composite results on adhesive property on bone

surface and titanium implant, when adding halloysite into PMMA bone cement the
adhesive property shows a significant increase of 5 times when 7.5 wt% halloysite is
added. According to this result, we propose to add halloysite into any kind of glue to find
out if additional halloysite can enhance the adhesive property on a porous surface. In this
study, ceramic is used as the porous surface; epoxy glue and silicon glue are used to
examine the flexural strength o f halloysite glue composites (Figure 6-9).
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td

Figure 6-9: Glue composite three-point bending setup.
Figure 6-10 shows the strain-strain o f 2 wt% halloysite/epoxy glue composite.
Adding 2 wt% halloysite into epoxy glue, the stress increases about 4 times, and the max
force to break two pieces o f ceramic increase about 8 times. The water contact angle
increases from 40±5° for epoxy glue to 70±5° for the halloysite epoxy glue composite.
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Figure 6-10: Halloysite/epoxy glue composite adhesive strength and water contact angle
for halloysite/epoxy glue composite (40±5°to 70±5°).
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Figure 6-11 shows the strain-strain o f 4.4 wt% halloysite/silicone glue composite.
Adding 4.4 wt% halloysite into the silicone glue, the stress increases about 3 times, and
the max force to break two pieces o f ceramic increases from 1.6 MPa to 2.3 MPa. The
water contact angle decreases from 110±5° for epoxy glue to 90±5° for halloysite epoxy
composite.
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Figure 6-11: Halloysite/silicone glue composite adhesive strength and water contact angle
for halloysite/epoxy glue composite (1 10±5°to 90±5°).
6.3.9

PMMA/Hallovsite Composite Thermal Effects
PMMA polymerization is an exothermic process with the heat effect of

55 kJ/mole which causes heating as high as 70 °C, and causing thermal necrosis o f the
surrounding tissue. The addition o f 10 wt% halloysite by weight effectively reduced the
temperature peak down to 50 °C (Figure 6-12), which is safe for surrounding tissue, if we
consider that the duration o f this state is less than 90 sec.
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Figure 6-12: Temperature o f PMMA cement composites during polymerization process
for pure PMMA and cement doped with halloysite.
6.3.10

Antibiotics Release from Bone Cement
Gentamicin was loaded into halloysite using vacuum cycling, as described earlier.

Before washing the sample, gentamicin comprised ca. 15% o f the total mass o f the
nanotubes. After two brief rinses, the gentamicin amount was reduced to 11% and was
probably located within the tube (lumen volume is ca. 10% of the halloysite tube). The
lost gentamicin may be associated with the outer surface o f the tubes. The outer surface
o f halloysite is primarily silica-based and has a negative charge. Gentamicin, having an
isoelectric point o f over 8.0, will have a small positive charge at pH 7 and may adsorb on
the outer surface o f halloysite. To observe the drug release from the tube interior, we
removed any bound gentamicin to the halloysite outer surface, through repeated washings
in DI water, leaving mostly gentamicin internalized in the halloysite lumen. For the
halloysite powder (without PMMA) 94% o f loaded gentamicin was released within 48
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hours. However, gentamicin release was drastically extended with the halloysite
incorporated in the PMMA.
For the PMMA bone cement composite doped with clay nanotubes, gentamicin
loaded halloysite was admixed to MMA monomer. During PMMA solidification,
additional encasing o f the antibiotic inside the tube occurred. Release from PMMA
composites became much slower and reached ca. 60% in 250 hours. Figure 6-13 presents
the gentamicin release profiles from the PMMA bone cements admixed with different
quantities of loaded halloysite. There are two groups of results presented: in
Figure 6-13 a cement doped with gentamicin is encapsulated in the tubes, and in
Figure 6-13 b samples with combined 1.5 wt% free gentamicin admixing and doping with
loaded halloysite. The data clearly show that more gentamicin is released from the
samples with a larger halloysite percentage.
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Figure 6-13: Gentamicin release from PMMA / halloysite composites: a) corresponds to
the samples doped with only loaded halloysite (halloysite was loaded with gentamicin
prior to mixing with PMMA). b) Corresponds to the samples with 1.5 wt% of free
gentamicin in addition to loaded halloysite. Weight of the samples is 150±10 mg [83].
The amount o f gentamicin leakage from bone cement samples modified with
halloysite nanotubes is lower than the ones containing both free gentamicin and
halloysite. This is due to the partial blocking of the halloysite tube endings by the PMMA

92

polymer matrix. Admixing 1.5 wt% o f additional free gentamicin allowed for double
antibiotic release. The combination o f free gentamicin and loaded halloysite tubes as
additives allowed for higher antibiotic loading with faster initial release without
compromising the mechanical strength (Figure 6-13 b) the bottom curve corresponds to
the samples with only 1.5 wt% of free gentamicin and the higher curves demonstrate the
addition of loaded halloysite).
There is an interesting feature o f induced gentamicin release in the PMMA/loaded
halloysite composite in implant defects (such as cracks) (Figure 6-14). Additional
gentamicin leakage was observed after the cracking o f the composite sample, which was
due to the additional exposure of the internal halloysite tubules. This result also
demonstrated that the total amount o f gentamicin release from the composite was equal to
the release from the halloysite. When cracks appear on the composite after surgery, the
jum p in release will provide a fast release of antibiotics to protect against infection.
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Figure 6-14: Gentamicin release for 48 hours. Red line shows gentamicin release from
150 mg of PMMA composite containing 15 mg o f halloysite. After 48 hours, the PMMA
sample was crushed; this resulted in additional release [83].
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Figure 6-15 presents the ciprofloxacin release profiles from the PMMA bone
cements admixed with different quantities o f loaded halloysite for 2 weeks. There was
about 70% of ciprofloxacin released from each sample over two weeks.
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Figure 6-15: Ciprofloxacin release from PMMA / halloysite composites.
The reason antibiotics released slower from the PMMA/halloysite composites
than from the halloysite nanotube was that the release from composites has two steps,
first, antibiotics release from halloysite nanotube to the composite matrix, second, the
antibiotics in the composite matrix release to the outside environment. The composite o f
PMMA and antibiotics loaded halloysite demonstrated a longer and slow release of
antibiotics, and the potential for additional fast release when a crack appears.
6.3.11

Antibacterial Effect o f Gentamicin Loaded Halloysite Doped in PMMA
Preventing infection is an important aspect o f implant surgery. Gentamicin is

bactericidal on proliferating and resting pathogens and often is used for bone cement.
With its broad therapeutic spectrum, gentamicin covers a variety o f gram-positive and
gram-negative bacteria. We used the antibiotic gentamicin to demonstrate its efficiency
after encapsulating it in halloysite nanotubes doped into bone cement. Encapsulation in
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halloysite tubes allowed for sustained release of gentamicin, giving a prolonged
antibacterial effect.
In Figure 6-16, images o f the bacterial growth o f E. Coli (a, b) and S. aureus (c, d)
cultures around PMMA cement and PMMA + 7.5 wt% gentamicin loaded halloysite are
presented. Unloaded cement and gentamicin loaded halloysite/PMMA bone cement
squares were placed onto bacterial streak cultures. Bacteria readily grew around unloaded
PMMA composites (Figure 6-16 a, c). The cement composite with gentamicin-loaded
halloysite inhibited bacterial growth (Figure 6-16 b, d). These results show that the
release o f antibiotics, such as gentamiein from the PMMA/halloysite composite can help
solve the infection problem without compromising the implant mechanical strength for
halloysite doped PMMA composites.

Figure 6-16: Images o f E. coli (a, b) and S. aureus (c, d) around original PMMA cement
(left images), and PMMA + 7.5 wt% halloysite loaded with gentamicin (right images)
after one week o f the bacterial culture growth [83].
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6.3.12

Tricalcium Phosphate Bone Cement Halloysite Composites
In this project, another bone cement, tricalcium phosphate, was also studied for its

mechanical properties when add halloysite to make composites. Tricalcium phosphate
bone cement will be prepared by mixing 1 gram o f powdered /Ttricalcium phosphate
halloysite mixture with 0.35 ml o f 20% citric acid solution. Then the sample will be
placed into molds with the desired shape and dried for one day before testing.
Halloysite tricalcium phosphate bone cements were prepared by interaction of
/Ttricalcium phosphate with citric acid solution. 4 grams o f the powder containing a
mixture o f halloysite and /toricalcium phosphate was thoroughly mixed with 1.4 ml o f
20% citric acid solution and left one day for complete hardening. Original calcium
phosphate cement has a white color that turns creamy yellow upon the addition o f
halloysite (Figure 6-17). The addition of 10-20 wt% halloysite into calcium phosphate
cement gives a reasonably good distribution within the cement matrix. Formation of a
microfibrous network in halloysite admixed calcium phosphate cement significantly
improves the mechanical properties o f the cement. SEM images indicate calcium
phosphate fibers of ca. 50 micron length with an aspect ratio o f close to 100.

Figure 6-17: Tricalciumphosphate bone cement composites (a). Halloysite initiates non
isotropic crystallization of calcium phosphate yielding fibers o f 50 microns length and
0.5 micron diameter (b-c).
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Mechanical strength of tricalciumphosphate bone cement composites was
compressed to determine the maximum force needed to break the composite. Figure 6-18
shows that the peak force needed to break the composite significantly increased from
25±5 N to 200±20 N. Figure 6-19 shows the strain-stress curve of
halloysite/tricalciumphosphate bone cement composites.
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Figure 6-18: Peak force needed to break halloysite/tricalciumphosphate bone cement
composites.
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Figure 6-19: Strain-Stress curve o f halloysite/tricalciumphosphate bone cement
composites.
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6.4

Conclusions

We have shown that PMMA bone cement doped with 5-7 wt% gentamiein-loaded
halloysite nanotubes provides for slow 100-300 hours release o f gentamicin without
compromising the mechanical strength o f the composite. There is only a slight difference
between 5-7 wt% loaded halloysite/PMMA composite. The addition o f PMMA/halloysite
composites to bacterial cultures and the subsequent sustained gentamicin release,
efficiently inhibited bacterial growth o f E. coli and S. aureus. The addition of halloysite
into PMMA improved the mechanical properties of the bone cement including higher
tensile strength, and significant gains in adhesive strength. The flexural strength o f the
samples was slightly decreased at a higher ratio of halloysite content. Measurements of
PMMA/halloysite adhesiveness on femoral bone showed a fivefold increase when 7 wt%
halloysite was added. Based on the overall measurements, we concluded that 5 - 7.5 wt%
of halloysite is the optimal amount to be added to PMMA bone cement to achieve the
best mechanical and adhesive properties as well as high storage and sustained release
capabilities for antimicrobial gentamicin.
A similar approach was used for halloysite loading in another commonly used
bone cement- tricalcium phosphate (CP). We managed to overcome mechanical
weakness of this material by increasing its tensile strength 5-6 times by doping it with
halloysite nanotubes.

CHAPTER 7
CONCLUSIONS AND FUTURE W ORK
7.1

Conclusions

In this dissertation, halloysite nanotubes were studied as nano-containers for
loaded and sustained controlled release o f drugs (antiseptics and antibiotics). Drug loaded
halloysite tubes were mixed with bulk materials, such as PMMA and CP bone cements
and polymeric paints, to make nanocomposites with new antibacterial properties. The
polymer/halloysite composites showed synergetic improvement of materials’ mechanical
properties and provided a controlled release o f loaded medical substances.
Usually, non-formulated drug powders dissolve in water within 10-15 minutes
allowing for time-limited efficiency. However, drugs loaded in halloysite tubes release
slowly for tens o f hours. Because the lumen volume of halloysite is about 10-15%, the
loading efficiency and release rate are controlled by the lumen size. In order to get higher
loading efficiency, halloysite was modified by selective etching of the inner lumen
alumina allowing an increase in the loading from 10 to 35 wt%.
Reducing drugs release rate was another important factor for this nano
formulation. An additional stopper coating was synthesized by copper-benzotriazole
(BTA-Cu) coating predominantly at tube endings. Brilliant green loaded halloysite with
BTA-Cu stoppers significantly (3-5 times) reduced the release rate. Brilliant green release
from halloysite without a stopper reached about 70% in 3 hours; while on the other hand,

71

99

the release with BTA-Cu stopper only reached 5% in 3 hours. The additional BTA-Cu
stopper also increase the loading efficiency: without a stopper it was 3%, and with a
stopper - increased up to 18%. The BTA-Cu stopper formations were optimized
depending on the concentration of both compounds. The higher concentration of both
compounds will form a tighter coating with small pores, giving slower release. If one of
the compound concentrations was much lower than the other, the coating has larger pores
which led to more leakage.
Next, we studied antibacterial efficiency o f encased antiseptics (brilliant green,
amoxicillin, iodine). Brilliant green loaded halloysite with and without a stopper killed
S. aureus for a 72 hour time period, while in a control experiment using on-formulated
brilliant green powder only worked for 3 hours.
A similar strong increase in the efficiency was obtained for antibiotics /halloysite
formulations (ciprofloxacin and gentamicin). The antibacterial effect o f ciprofloxacin
only lasts for 24hours, but halloysite loaded ciprofloxacin worked for 72 hours allowing
for the efficient suppression o f MDR (drug resistant) gangrene bacteria.
Other antibacterial nanocomposites were made using inner-tubule silver
encapsulation. Halloysite can be used as a template to synthesize metal nanorods in the
lumen. Silver nanorods were synthesized in 15 nm diameter halloysite lumens allowing
for core-shell metal-ceramic nanostructures where metals are protected from quick
oxidation. Doping encapsulated silver/clay nanorods into paint, the paint composites
presented strong antimicrobial properties combined with an enhancement o f the coatings
tensile strength. The results show that most of the antimicrobial efficiency was located
around cracks in the paint composite where enhanced release of silver ions occurred.
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Another advantage o f encasing silver nanorods in halloysite tube was preventing silver
decomposition under intensive UV light (the paint composite preserved its color).
Further research development was the loading o f halloysite with antibiotics and
doping them into bone cements. The composites o f polymethylmethacrylate - PMMA
with halloysite solved the limitations of adding non-formulated antibiotics in PMMA
bone cement (preserved antibiotics efficiency and enhanced composite strength). First,
adding 5-7.5 wt% halloysite into PMMA bone cement did decrease the mechanical
properties o f the composites. The results show an increasing of tensile strength, and a
slight decreasing of flexural strength. Surprisingly, the adhesivity of PMMA bone cement
on bone surface and titanium implants significantly increased. Second, antibiotics loaded
in halloysite nanotube and then mixed with PMMA bone cement provided slow 150-200
hours release o f gentamicin (this one week time is a typical demand for orthopedic
surgery post-treatment). Besides, if tension or crack appeared at the bone cement
composite, it led to a response o f faster release o f antibiotics at the crack section. Third,
the added halloysite in PMMA bone cement decreased the polymerization temperature
from 70 to 55 °C (by references o f practical surgeons in the LSU-Shreveport hospital, this
will allow a decrease in tissue burning during orthopedic surgery).
A similar technique of halloysite doping into another mechanically weak bone
cement - tricalcium phosphate (CP) allowed for a substantial5-7 times increase o f its
mechanical strength, widening applications for CP.
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7.2

7.2.1

Future W ork

Selective Modify Halloysite to Improve Loading and Release
One disadvantage of halloysite is the lumen volume o f just about 10% which

limited the loading efficiency. This dissertation gave preliminary results on sulfate acid
etching o f the halloysite lumen. The more etching, the larger was the lumen diameter that
was obtained. However, the increase o f the lumen diameter leads to faster release o f the
loaded substance. This work on the halloysite lumen size optimization will be preceded in
Dr. Lvov’s group.
Another way to improve tube loading and release is to alter its physical-chemical
properties. As we know, the inner lumen of halloysite is aluminum based, and it is
positively charged and hydrophilic. This is not good for a load that is positively charged
or for hydrophobic substances. One can modify the surface properties o f the tube lumen
by reversing its charge or making it hydrophobic, for example, through silanisation. This
work is also under development.
End-stoppers: the tube opening is controlling the release kinetics. In this work,
BTA-Cu tube coating has already been studied, however, even though these stoppers can
significantly decrease release, copper ions were noted as heavy metal and potentially
harmful for biomedical applications. So, synthesis o f a biocompatible stopper is needed
(probably based on iron complexation).
This dissertation presents a number o f simple methods for improving halloysite
drug loading and extended release. For future work, one could combine and optimize
these methods to reach higher loading efficiency and better controlled release.
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We presented the different kinetics o f the drugs release from halloysite; some o f
the drugs release faster, some released slowly. So, by mixing, in one formulation,
halloysite loaded with different drugs, one can get the needed multidrug release pattern.
In this way, we can get a series release o f multiple drugs depending on time. The most
important idea o f the dissertation, the increased efficiency o f drugs loaded into clay
nanotubes, may be developed to fight multidrug resistant bacteria.
7.2.2

Metal Loaded Halloysite for X-ray Detection
X-ray is a common way to examine bone injury and recovery. In Chapter Five, a

method is described on how to use halloysite as a template to make metal nanorods in the
halloysite lumen. Based on this method, halloysite can be used to load some x-ray
detection chemicals such as barium sulfate, then add this halloysite to PMMA bone
cement, which will help to examine the bone cement using x-rays.
7.2.3

Other Biopolymer/Hallovsite Composites
According to the results obtained for PMMA/halloysite composites, add loaded

biocompatible natural halloysite nanotubes into biopolymers to make a composite. The
composite will then provide a slow release o f the loaded substance and, with the
synergistic enhancement of mechanical properties, such as tensile strength, flexural
strength, and adhesive strength. A similar biomaterial is artificial teeth. Dr. Lvov's group
recently established contacts with LSU Dental School in New Orleans. We will work on
an artificial halloysite composite for adhesive and antibacterial teeth fillings.
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